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Abstract 
P r o s t a t e   c a n c e r   i s   t h e   m o s t   f r e q u e n t l y   d i a g n o s e d   m a l i g n a n c y   i n   A m e r i c a n   m e n ,   a n d   a   m o r e  
aggressive f o r m   o f   t h e   d i s e a s e   i s   p a r t i c u l a r l y   p r e v a l e n t   a m o n g   A f r i c a n   A m e r i c a n s .   T h e   t h e-
r a p e u t i c   s u c c e s s   r a t e   f o r   p r o s t a t e   c a n c e r   c a n   b e   t r e m e n d o u s l y   i m p r o v e d   i f   t h e   d i s e a s e   i s  
d i a g n o s e d   e a r l y .   T h u s ,   a   s u c c e s s f u l   t h e r a p y   f o r   t h i s   d i s e a s e   d e p e n d s   h e a v i l y   o n   t h e   c l i n i cal 
i n d i c a t o r s   ( b i o m a r k e r s )   f o r   e a r l y   d e t e c t i o n   o f   t h e   p r e s e n c e   a n d   p r o g r e s s i o n   o f   t h e   d i s e a s e ,   a s  
well as the prediction after the clinical intervention. However, the current clinical biomarkers 
for prostate cancer are not ideal as there remains a lack of reliable biomarkers that can 
specifically distinguish between those patients who should be treated adequately to stop the 
a g g r e s s i v e   f o r m   o f   t h e   d i s e a s e   a n d   t h o s e   w h o   s h o u l d   a v o i d   o v e r t r e a t m e n t   o f   t h e   i n d o l e n t  
form.  
A   b i o m a r k e r   i s   a   characteristic that is objectively measured and evaluated as an indicator of 
normal biologic processes, pathogenic processes, or pharmacologic responses to a thera-
peutic intervention. A biomarker reveals further information to presently existing clinical and 
pathological analysis. It facilitates screening and detecting the cancer, monitoring the pro-
gression of the disease, and predicting the prognosis and survival after clinical intervention. A 
biomarker can also be used to evaluate the process of drug development, and, optimally, to 
improve the efficacy and safety of cancer treatment by enabling physicians to tailor treatment 
f o r   i n d i v i d u a l   p a t i e n t s .   T h e   f o r m   o f   t h e   p r o s t a t e   c a n c e r   b i o m a r k e r s   c a n   v a r y   f r o m   m e t a b o l i t e s  
and chemical products present in body fluid to genes and proteins in the prostate tissues.  
Current advances in molecular techniques have provided new tools facilitating the discovery 
of new biomarkers for prostate cancer. These emerging biomarkers will be beneficial and 
critical in developing new and clinically reliable indicators that will have a high specificity for 
the diagnosis and prognosis of prostate cancer. The purpose of this review is to examine the 
current status of prostate cancer biomarkers, with special emphasis on emerging markers, by 
evaluating their diagnostic and prognostic potentials. Both genes and proteins that reveal loss, 
mutation, or variation in expression between normal prostate and cancerous prostate tissues 
will be covered in this article. Along with the discovery of prostate cancer biomarkers, we will 
describe the criteria used when selecting potential biomarkers for further development to-
wards clinical use. In addition, we will address how to appraise and validate candidate markers 
for prostate cancer and some relevant issues involved in these processes. We will also discuss 
the new concept of the biomarkers, existing challenges, and perspectives of biomarker de-
velopment.  
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1. Introduction 
Epidemiology of prostate cancer 
With  an  estimated  192,280  new  cases  in  2009, 
prostate  ca n c e r   i s   o n e   o f   t h e   m o s t   c o m m o n l y   d i a g-
nosed malignancies in American men (1). It is also the 
second  leading  cause  of  cancer  death  in  American 
m a l e s ,   e x c e e d e d   o n l y   b y   l u n g   c a n c e r .   A n   e s t i m a t e d  
27,360 men will die from prostate cancer in 2009 (1). 
Prostate cancer i s   a   d i s e a s e   o f   m a i n l y   o l d e r   m e n .  
A n   e a r l y  o b s e r v a t i o n   r e p o r t s   t h a t   m o r e   t h a n   6 5 %   o f   a l l  
prostate cancers are diagnosed in men over the age of 
65 (2). Compared with the occurrences in the White 
population,  the  incidence  of  prostate  cancer  is  ap-
p r o x i m a t e l y   6 0 %   h i g h e r   i n   B l a c k   m e n ,   w h i l e   n a t i v e  
J a p a n e s e   a n d   C h i n e s e   p o p u l a t i o n s   h a v e   a   l o w   r i s k   o f  
incidence  and  mortality  (3).  Furthermore,  Afri-
can-American  men  generally  are  diagnosed  with 
more advanced stages of prostate cancer and at an 
earlier  a g e   ( 4 ) .   C o n s e q u e n t l y ,   m u c h   e f f o r t   i s   b e i n g  
p l a c e d   o n   d e t e c t i n g   p r o s t a t e   c a n c e r   i n   a n   e a r l y ,   c u r a-
b l e   s t a g e   t o   d e c r e a s e   t h e   r a t e   o f   m o r t a l i t y   f r o m   t h i s  
disease. Along with genetics, social and environmen-
tal factors (especially diet and lifestyle) may act as the 
d e t e r m i n i n g   f a c t o r s ,   w h i c h   m a y   e x p l a i n   w h y   s o m e  
individuals are at higher risk for developing prostate 
cancer  than  are  others. Nevertheless, in most cases, 
this disease can be treated effectively and even eradi-
cated  when  the  disease  is  detected  at  a  very  early 
stage (2). 
Biomarkers  
T h e   N a t i o n a l   C a n c e r   I n s t i t u t e   d e f i n e s   a   b i o-
marker  as  “a  biological  molecule  found  in  blood, 
o t h e r   b o d y   f l u i d s ,   o r   t i s s u e s   t h a t   i s   a   s i g n   o f   a   n o r m a l  
or abnormal process or of a condition or disease.” A 
biomarker  may  be  objectively  measured  and  eva-
luated as an indication of normal biologic processes, 
pathogenic processes, or pharmacologic responses to 
a particular treatment or condition (5-7). Biomarkers 
are widely used as analytical tools to assess biological 
parameters for a rapid and comprehensive therapeu-
tic  analysis.  In  addition,  biomarker  measures  can 
further the development and evaluation of new ther-
apies (8).  
In pilot studies involving therapeutic candidates, 
biomarkers  can  be  used  as  criteria  for  deciding  on 
lead comp o u n d s   f o r   t h e   t h i r d   p h a s e   o f   c l i n i c a l   t r i a l s  
( 8 ) .   T h e y   a l s o   h e l p   i n   t h e   u n d e r s t a n d i n g   o f   c l i n i c a l  
pharmacology, and are essential in the planning of 
clinical  trials,  which  strives  to  promptly  and  ulti-
mately assess safety and effectiveness (9, 10) (Table 1 
and 2). Biomarkers that represent highly sensitive and 
specific indicators of disease pathways are often used 
a s   s u b s t i t u t e s   f o r   o u t c o m e s   i n   c l i n i c a l   t r i a l s   w h e r e  
t h e y   c a n   b e   u s e d   t o   p r e d i c t   a n d   e v a l u a t e   t h e   c l i n i c a l  
risk  and/or  benefit  of  a  treatment,  which is the op-
timal objective of all therapeutic interventions (11). 
 
Table 1. Use of Cancer Biomarkers in Patient Care 
Use of Biomarker  Clinical Goal 
Risk Stratification  Used in evaluating the probability 
of the occurrence or recurrence of 
cancers.  
Chemoprevention  To determine and target the cellu-
lar and molecular mechanisms of 
carcinogenesis in preneoplastic 
tissues.  
Screening  Used to recognize early-stage 
cancers in the general population 
and administer early treatment. 
Diagnosis and Classification  Used to reliably determine and 
distinguish the presence and type 
of cancer. 
Prognosis  Helps in estimating the likely 
outcome of the disease, without 
considering treatment, to establish 
the intensity of treatment.  
Prediction of treatment  Anticipate the response to respec-
tive treatments and select the 
therapy with the highest probabil-
ity of being effective in a particular 
patient.  
Therapy Tracking and 
Post-treatment Surveillance 
Used in assessing the effectiveness 
and adverse effects of a treatment 
a n d   t o   p r o v i d e   e a r l y   d e t e r m i n a t i o n  
and treatment of recurrent disease. 
 
Table 2. Biomarker Application in Drug Development 
Use of Biomarker  Drug Development Goal 
Target Verification  Used to establish that a probable 
drug target executes a pivotal 
function in the physiology of the 
disease. 
Early Compound Selection  Determine the most favorable 
compounds in terms of safety and 
efficacy.  
Pharmacodynamic Assays  Used to ascertain the drug’s effect 
on the body to establish a dosing 
regimen. 
Patient Selection for Clinical 
Trials 
Aids in patient selection based on 
disease subtype or likelihood of 
positive response versus adverse 
reaction. 
Surrogate Endpoint in Drug 
Approval 
Used for a quick assessment of the 
safety and efficacy of the therapy 
by using a short-term outcome 
(biomarker) instead of a long-term 
primary endpoint. 
 
 
Types of cancer biomarkers 
 Cancer  biomarkers  are  usually  classified  into 
three categories: prognostic, predictive, and pharma-
codynamic. Prognostic biomarkers predict the natural 
course  of  the  cancer  and  to  distinguish  the  tumor’s 
outcome.  They  also  help  determine  whom  to  treat, 
h o w   a g g r e s s i v e l y   t o   t r e a t ,   a n d   w h i c h   c a n d i d a t e s   w i l l  
l i k e l y   r e s p o n d   t o   a   g i v e n   d r u g   a n d   t h e   m o s t   e f f e c t i v e  Journal of Cancer 2010, 1 
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dose.  Predictive  biomarkers  evaluate  the  probable 
benefit  of  a  particular  treatment.  Pharmacodynamic 
biomarkers assess the imminent treatment effects of a 
d r u g   o n   a   t u m o r   a n d   c a n   p o s s i b l y   d e t e r m i n e   t h e  
p r o p e r   d o s a g e   i n   t h e   e a r l y   s t a g e s   o f   c l i n i c a l   d e v e l o p-
ment of a new anticancer drug (12). 
Instead of analyzing the tumor cells themselves, 
t h e   m o l e c u l a r   c o m p o s i t i o n   o f   a   t u m o r   c a n   b e   i n d i-
rectly characterized by analyzing blood samples and 
searching  for  variations  in  serum  proteins,  thereby 
improving the precision of screening and curtailing 
the  need   f o r   i n v a s i v e   d i a g n o s t i c   p r o c e d u r e s .   Some 
difficulties were encountered initially in an attempt to 
reproduce these cancer-specific serum proteins. With 
advances  in  our  ability  to  measure  quantitatively, 
collect standardized samples, and resolve the prob-
lems of reduced sensitivity in detection, confidence in 
the results of this approach has risen (12). Measure-
m e n t s   f r o m   b i o m a r k e r s   c a n   b e   u s e d   t o   a d j u s t   e m p i r i-
cal results of clinical trials by establishing a relation-
ship between the effects of interventions on molecu-
lar/cellular pathways and clinical responses, thereby 
p r o v i d i n g   a   w a y   f o r   s c i e n t i s t s   t o   c o m p r e h e n d   m e c h a-
nistically the differences in clinical response that may 
be affected by uncontrolled variables (5).  
2. BIOLOGY AND STAGING OF ROSTATE 
CANCER 
Biology of prostate cancer  
L o c a t e d   u n d e r   t h e   b l a d d e r   a n d   i n   f r o n t   o f   t h e  
rectum,  the  prostate  is  a  small,  soft  gland  with  the 
urethra  running  directly  through  it  (2).  Androgens 
regulate the prostate gland as the major stimulus for 
cell  division  in  prostatic  epithelium  (13).  Although 
androgens  are  regarded  as  major  contributors  to 
prostatic carcinogenesis, there is little direct evidence 
to demonstrate that androgens cause prostate cancer. 
I n   p a r t   b e c a u s e   o f   t h e   l a c k   o f   e a s i l y   m e a s u r a b l e   h o r-
monal events in men, there is insufficient evidence to 
establish an indirect role for androgens relative to the 
cause of the disease (14). 
P r o s t a t e   c a n c e r   o c c u r s   w h e n   t h e   r a t e   o f   c e l l   d i v i-
sion  surpasses  cell  death,  leading  to  uncontrolled 
tumor  growth.  Subsequent  to  the  initial transforma-
tion event, further mutations of a multitude of genes, 
i n c l u d i n g   t h e   g e n e s   f o r   p 5 3   a n d   r e t i n o b l a s t o m a ,   c a n  
r e s u l t   i n   t u m o r   p r o g r e s s i o n   a n d   m e t a s t a s i s   ( 1 5 ) .   M o r e  
than  95%  of  prostate  cancers  are  adenocarcinomas 
that arise from prostatic epi t h e l i a l   c e l l s   ( 1 6 ) .   O f   t h e s e  
cases, 70% occur in the peripheral zone, 15-20% in the 
central zone, and 10-15% in the transitional zone. The 
majority of cancer cells are multifocal and influenced 
simultaneously by numerous regions of the prostate 
gland, indicating that prostate cancer is probably the 
r e s u l t   o f   c l o n a l   a n d   n o n c l o n a l   t u m o r s   ( 1 5 ) .   T h e   c e l l s  
f r o m   t h e s e   t u m o r s   c a n   m e t a s t a s i z e   t h r o u g h   t h e   l y m-
phatic system and the bloodstream if untreated and 
allowed to grow. Arriving at their final destination, 
the  tumor  cells  lodge  and  grow  secondary  tumors, 
resulting in a dramatic decline in the cure rates for the 
disease. The presence of these prostate cancer cells in 
another site, such as bone, does not change its classi-
fication to bone cancer–for instance. The new tumor is 
still considered to be prostate cancer (2).  
There is an architectural and cytological similar-
ity between prostate cancers identified clinically and 
those detected incidentally at autopsy, although dif-
ferences  do  exist  in  numerous  pathologic  features. 
Compared  to  the  clinically  identified  cancers,  inci-
dentally found cancers are usually small, sufficiently 
or  moderately  differentiated,  and  confined  to  the 
prostate  (17-21).  In  addition,  unsuspected  prostate 
cancers  found  at  the  time  of  cystoprostatectomy  for 
t h e   t r e a t m e n t   o f   b l a d d e r   c a n c e r   a r e   s i m i l a r   t o   a u t o p s y  
cancers  (20).  Seventy-eight  percent  of  unexpected 
prostate  cancers  found  in  cystoprostatectomy  speci-
mens  are  small,  confined  to  the  prostate,  and  mod-
erately to well differentiated, compared with only 9% 
of  the  clinically  detected  cancers  with  such  features 
(19).  Twenty-nine percent of clinically found cancers 
a r e   a d v a n c e d   a s   c o m p a r e d   w i t h   n o n e   o f   t h e   c y s t o-
prostatectomy cancers (22). 
Prostate cancer staging systems 
Stage and grade classification of a tumor is fre-
quently complemented by the biomarker expression 
when biologically targeted therapeutics are discussed. 
T h e   s t a g e   o f   t h e   c a n c e r   i n d i c a t e s   c e r t a i n   a s p e c t s   o f   t h e  
c a n c e r   s u c h   a s   t h e   t u m o r   s i z e ,   d e p t h   o f   i t s   p e n e t r a t i o n ,  
extent to which the cancer has spread, and to which 
o r g a n ( s )   i t   h a s   m e t a s t a s i z e d   a n d   i n v a d e d ,   a s   w e l l   a s  
i t s   e f f e c t   o n   t h e   o r g a n ( s )   i n   r e l a t i o n   t o   t h e   s t a g e  (23). 
T h e   s t a g e   a t   d i a g n o s i s   o f   c a n c e r   i s   c o n s i d e r e d   t h e   m o s t  
important indicator regarding survival of the patient. 
S t a g e   i s   a l s o   v e r y   i m p o r t a n t   b e c a u s e   t h e   r e q u i r e d  
therapy  i s   d i r e c t l y   r e l a t e d   t o   a n d   f r e q u e n t l y   v a r i e d  
based on it (24). 
Two  main  classification  systems  are  used  to 
stage tumors: the Jewett system (stages A through D) 
described  in  1975  and  since  modified  (25)  and  the 
T N M   s y s t e m   a d o p t e d   i n   1 9 9 7   b y   t h e   A m e r i c a n   J o i n t  
Committee  on  Cancer  (AJCC)  and  the  International 
U n i o n   a g a i n s t   C a n c e r .   I n   2 0 0 2 ,   t h e   T N M   c l a s s i f i c a t i o n  
s y s t e m   w a s   f u r t h e r   r e v i s e d   b y   t h e   A J C C   ( 2 6 ) .   T h e s e  
systems can reveal nonpalpable tumors by identifying 
an increase in serum prostate-specific antigen (PSA) 
level  or  an  aberrant  transrectal  ultrasound  image. Journal of Cancer 2010, 1 
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These systems can also categorize patients based on 
tumor detection technique and distinguish nonpalpa-
ble  prostate  cancers  (those  detected  during  transu-
rethral resection) from palpable ones (those detected 
by digital rectal examination) (27). 
The TNM staging system is based on the extent 
of  the  tumor  size  and  grade  (T),  detection  in  the 
l y m p h   n o d e s   ( N ) ,   a n d   a n y   o t h e r   p o s s i b l e   m e t a s t a s i s  
(M)  ( 2 8 ) .   I t   c o r r e s p o n d s   t o   o n e   o f   f i v e   s t a g e s   o f   t h e  
traditional staging system (a progression of the cancer 
f r o m   S t a g e   0   t o   S t a g e   I V ) ,   b u t   i t   h a s   t h e   a d v a n t a g e   o f  
revealing more detail by separating designations for 
the primary tumor, regional nodes, and distant  me-
tastases  via  more  specific  alphanumeric  subcatego-
ries. An added number or letter is used to specify the 
size or extent of the tumor and the extent of spread (2, 
2 7 )   ( T a b l e   3 ) .   T h e   s t a g i n g   s y s t e m   i s   i m p o r t a n t   a n d  
essential,  however  insufficient  it  is  by  itself.  Other 
significant variables that may contribute to the evalu-
ation include the grade; PSA level; DNA ploidy; nuc-
lear morphometry; and a number of cellular, molecu-
lar, genetic, and environmental factors (29). 
Knowledge of the stage of disease facilitates de-
t e r m i n i n g   h o w   a g g r e s s i v e l y   t o   t r e a t   t h e   d i s e a s e   a n d  
how likely the available treatment options will elimi-
nate  the  disease  (2).  Although it can be difficult to 
accurately stage the cancer, incorrect staging can re-
sult in improper treatment and substantial decrease in 
the patient’s chance of survival (23). The results from 
some  common  tests  like  digital  rectal  examination 
( D R E ) ,   s e r u m   P S A   t e s t ,   o r   t r a n s r e c t a l   u l t r a s o u n d  
( T R U S )   c a n   r e v e a l   t h e   p r o b a b i l i t y   o f   t h e   i n c i d e n c e   o f  
prostate c a n c e r .   A n y   p ositive cases from these tests 
are usually followed by biopsy and histological ex-
amination  for  verification.  Several  other  tests,  in-
cluding X-rays, MRIs, CT scans, and bone scans, can 
then be used to determine the stage of cancer and to 
detect any localized cancers outside the prostate (2). 
Despite the fact that the staging systems can reveal the 
extent of disease, t h e   t e s t   r e s u l t s   c a n n o t   b e   u s e d   i n-
dependently to ascertain the stage of the disease, to 
select the best treatment options, or to envisage out-
comes because they are not capable of detecting very 
small groups of cancer cells (30). 
 
Table 3 The TNM Staging System 
Primary Tumor (T)  Early Stage  Advanced Stage 
  TX: Primary tumor cannot be evaluated   
  T0: No evidence of primary tumor   
  T1: Although the tumor is present, it is clinically not 
palpable or visible by imaging. It may have been de-
tected by needle biopsy, after finding a raised PSA level 
 
    T1a: Found incidental to other surgery; tumor was inciden-
tally found in less than 5% of prostate tissue resected (for 
other reasons) 
    T 1 b :   F o u n d   i n c i d e n t a l   t o   o t h e r   s u r g e r y ;   p r e s e n t   i n   5 %   o r   m o r e  
of tissue 
    T1c: Identified by needle biopsy performed a result of  an 
elevated serum PSA 
  T2: Tumor confined within prostate, the tumor can be 
palpated on examination, but has not spread outside 
the prostate 
 
    T2a:  the tumor is in half or less than half of one of the pros-
tate gland's two lobes 
    T2b: the tumor is in more than half of one lobe, but not both 
    T2c: The tumor is in both lobes but is still inside the prostate 
gland    
  T3: Tumor extends through prostate capsule    
    T 3 a :   t h e   t u m o r   h a s   s p r e a d   t h r o u g h   t h e   c a p s u l e   o n   o n e   o r   b o t h  
sides 
    T3b: the tumor has invaded one or both seminal vesicles 
    T3c Extends into seminal vesicles 
  T4: The tumor has spread into other body organs 
nearby, such as the rectum or bladder 
 
    T4a: Invades bladder neck, external sphincter, or rectum 
    T4b: Invades muscles and/or pelvic wall 
Regional Lymph 
Nodes (N) 
   
  NX: Regional lymph nodes cannot be evaluated   
  N0: No regional lymph node involvement; no cancer 
cells found in any lymph nodes  
 
  N1: One positive lymph node smaller than 2 cm 
across, there has been spread to the regional lymph 
nodes 
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  N2: More than one positive lymph node Or one that is 
between 2 and 5cm across    
 
  N3: Any positive lymph node that is bigger than 5 cm 
across  
 
Distant Metastasis 
(M) 
   
  MX: Distant metastasis cannot be evaluated   
  M0: No distant metastasis    
   M1: there is distant metastasis   
    M1a: the cancer has spread to lymph nodes beyond the re-
gional ones 
    M1b: the cancer has spread to bone 
    M1c: the cancer has spread to other sites  
The TNM staging system based primarily on the anatomical extent of disease, which considers the tumor size or depth (T), lymph node 
spread (N), and presence or absence of metastases (M). The TNM system is used as a standard for staging and predicting survival, choice of 
early treatment, and stratification of patients in clinical trials.  
 
 
3. SCREENING FOR PROSTATE CANCER 
Prostate cancer generally does not present any 
symptoms until it becomes locally advanced or me-
tastatic  disea s e .   T h e r e f o r e ,   i n   t h e   p a s t ,   e f f o r t s   a t  
screening and early detection have used all available 
tools  for  diagnosis  in  asymptomatic  patients  before 
the presentation of symptoms (14). The detection and 
management of prostate cancer is controversial, espe-
cially  regarding  screening  and  therapy  choice  after 
diagnosis. For example, a patient can be diagnosed 
l a t e   i n   l i f e   w i t h   a   l o w -g r a d e   p r o s t a t e   c a n c e r   t h a t   m a y  
n o t   h a v e   a n y   i m p a c t   o n   t h e   q u a l i t y   o r   l e n g t h   o f   h i s  
l i f e ,   w h i l e   a   y o u n g e r   m a n   w i t h   a   h i g h -grade lesion can 
h a v e   a n   a d v a n c e d   d i s e a s e   a n d   d i e   w i t h i n   5   y e a r s   b e-
cause  of  the  disease’s  aggressive  progression.  This 
intriguing observation demonstrates the unusual bi-
o l o g i c a l   h e t e r o g e n e i t y   o f   p r o s t a t e   c a n c e r   a n d   d e-
mands distinctive classification (14). 
Nonetheless,  a  greater  number  of  patients  are 
n o w   d i a g n o s e d   a t   a n   e a r l i e r   s t a g e   t h a n k s   t o   t h e   a d-
vanced  tools  for  prostate  cancer  diagnosis  that  has 
improved  considerably  in  recent  years.  Just  as  the 
screening and early diagnosis techniques for cervical 
and  breast  cancer   h a v e   b e e n   s h o w n   t o   s u c c e s s f u l l y  
reduce the death rates, respectively, from these can-
cers,  screening  for  prostate  cancer  has  successfully 
accomplished the same goal ( 3 1 ) .   S o m e   o f   t h e   m a j o r  
techniques  used  in  assessing  prostate  cancer  in  its 
early stage are   t h e   D R E ,   P S A   b l o o d   t e s t ,   a n d   T R U S  
(31, 32).  
DRE is regarded as a basic tool for screening and 
early detection of prostate cancer and is estimated to 
have about a 59% overall accuracy (33). Despite its 
seemingly poor sensitivity, DRE is a routine method 
for prostate cancer screening because it often detects 
c a n c e r s   m i s s e d   b y   o t h e r   t e s t s   ( 3 4 ) .   I t s   m a i n   a d v a n t a g e  
i s   t h a t   i t   m a y   d e t e c t   c a n c e r   i n   s o m e   m e n   w i t h   n o r m a l  
PSA levels and whose tumors are small and well dif-
ferentiated in  most  cases (33). An additional  advan-
t a g e   o f   D R E   i s   t h a t   i t   i s   a   r e l a t i v e l y   i n e x p e n s i v e   p r o-
c e d u r e   t h a t   i s   n o r m a l l y   w e l l   t o l e r a t e d ,   a n d   i t   c a n   b e  
u s e d   t o   i n v e s t i g a t e   o t h e r   a b n o r m a l   c o n d i t i o n s   o f   t h e  
p r o s t a t e ,   s u c h   a s   b e n i g n   p r o s t a t i c   h y p e r p l a s i a   ( B P H )  
( 3 5 ) .   T h e   m a i n   l i m i t a t i o n   o f   D R E   i s that most palpable 
cancers  are  not  early  cancers,  and  many  clinically 
i m p o r t a n t   c a n c e r s   a r e   l o c a t e d   i n   r e g i o n s   o f   t h e   g l a n d  
that are distant and thus evasive to digital palpation 
(34).  A  population-based case-control study on men 
w h o   d i e d   a s   a   r e s u l t   o f   prostate cancer reported that 
D R E   s c r e e n i n g   m i g h t   h a v e   p r e v e n t e d   a s   m a n y   a s   5 0   t o  
7 0 %   o f   t h e   d e a t h s   f r o m   t h e   d i s e a s e   ( 3 6 ) .   H o w e v e r ,  
controversial results from two other studies revealed 
t h a t   t h e r e   i s   n o   e v i d e n c e   t h a t   m e n   w h o   d i e d   a s   a   r e s u l t  
of prostate cancer were less likely to have received the 
s c r e e n i n g   c o m p a r e d   t o   t h o s e   w h o   s u r v i v e d   ( 3 7 ,   3 8 ) .  
Based  on  studies  investigating  the  sensitivity  and 
specificity of DRE and its role in the early detection of 
prostate cancer, the majority of experts agree that de-
tection is less likely when using DRE independently 
a s   o p p o s e d   t o   D R E   i n   c o m b i n a t i o n   w i t h   o t h e r   p r e-
dictors (39). 
Serum prostate-specific antigenPSA, discovered 
in 1971, is considered the most important biomarker 
for detecting, staging, and monitoring cancer of the 
p r o s t a t e   i n   i t s   e a r l y   s t a g e   ( 4 0 -4 7 ) .   P S A   i s   a   m e m b e r   o f  
t h e   f a m i l y   o f   h u m a n   k a l l i k r e i n   p r o t e a s e s   w i t h   a   m o-
l e c u l a r   m a s s   o f   a p p r o x i m a t e l y   3 0   k D a   a n d   c h y m o-
tryptic-like activity. In serum, PSA is bound primarily 
by  α1-antichymotrypsin (ACT), an endogenous  pro-
tease inhibitor, and also by another similar inhibitor, 
α2-microglobulin (A2M). PSA was initially thought to 
be solely synthesized by epithelial cells of the prostate 
and thus was used as a biomarker for diagnosing and 
managing  prostate  cancer  (48) .   H o w e v e r ,   P S A   h a s  
a l s o   b e e n   f o u n d   i n   a   v a r i e t y   o f   h u m a n   n o r m a l   a n d  
t u m o r   c e l l  lines and in biological fluids synthesized by Journal of Cancer 2010, 1 
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numerous  cells,  although  mainly  by  prostatic  epi-
thelial cells (46, 49). 
PSA  testing  was  initially  used  for  monitoring 
prostate  cancer  patients.  After  it  was  commercially 
introduced, it became extensively used for screening 
and diagnosing the disease. The noticeable increase in 
prostate  cancer  incidence  rates  in  the  United  States, 
w h i c h   s t a r t e d   i n   t h e   l a t e   1 9 8 0 s   a n d   p e a k e d   i n   1 9 9 2 ,  is 
believed  to  be  in  accordance  with  the  time  period 
w h e n   P S A   t e s t i n g   w a s   i n t r o d u c e d   ( 2 2 ) .   L i k e   D R E ,   P S A  
testing is a relatively inexpensive procedure and has 
high patient acceptance. The main advantage of PSA 
testing is its superior sensitivity. The main disadvan-
t a g e   o f   t h e   t e s t   i s   t h a t   i t   i s   n o t   v e r y   s p e c i f i c   b e c a u s e  
common  pathological  conditions  such  as  BPH  and 
p r o s t a t i t i s   c a n   a l s o   c a u s e   m o d e r a t e l y   t o   c o n s p i c u o u s l y  
abnormal test results. These false-positive results may 
l e a d   t o   f u r t h e r   d i a g n o s t i c   e v a l u ation, increasing costs 
and  use  of  more  invasive  procedures.  Conversely, 
e f f o r t s   t o   p r e v e n t   s u c h   o v e r d i a g n o s i s   t h a t   m a y   r e s u l t  
f r o m   t h e   h i g h   n u m b e r   o f   f a l s e -p o s i t i v e s   m a y   l e a d   t o  
delayed  treatment  for  the  aggressive,  potentially 
life-threatening cancers (22).  
In an effort to find ways of improving specificity, 
s e v e r a l   v a r i a t i o n s   o n   t h e   b a s i c   P S A   t e s t   h a v e   b e e n  
proposed. For example, the free PSA ratio, which may 
b e   a   m o r e   s p e c i f i c   t e s t ,   c o m p a r e s   t h e   a m o u n t   o f   f r e e  
PSA circulating in the blood (unbound) to the amount 
attached  to  other  blood  proteins  (50).  Furthermore, 
PSA levels are normally elevated in older men relative 
to younger men regardless of the absence or presence 
o f   c a n c e r .   T h e r e f o r e ,   a   c o n t i n u o u s   r i s e   i n   P S A   l e v e l  
o v e r   t i m e   f r o m   a   r e l a t i v e l y   l o w   level may be more 
indicative of cancer than a moderately increased PSA 
t h a t   i s   s t a g n a n t   ( 5 1 ) .   H i g h e r   P S A   v a l u e s   h a v e   a l s o  
been observed in African American men with newly 
diagnosed  prostate  cancer  when  compared  with 
n e w l y   d i a g n o s e d   C a u c a s i a n   m e n   ( 5 2 ) .   S t u d ies  have 
shown  that  African  American  men  have  notably 
larger cancer volumes even within clinical stage cat-
egory at diagnosis. Thus, special efforts at screening 
a r e   n e c e s s a r y   t o   m i n i m i z e   t h e   d i s c r e p a n c y .   I t   m a y   b e  
practical, therefore, to start testing at younger ages in 
A f r i c a n   A m e r i c a n   m e n   i n   a n   e f f o r t   t o   d e t e c t   t u m o r s  
earlier when they are still confined. Some researchers 
recommend  age-  and  race-a d j u s t e d   P S A   v a l u e s   f o r  
detecting cancer, with lower PSA limits for African 
American men (53-54).  
Serum PSA value  can  independently  predict  a 
pathological  stage.  However,  the  serum  PSA  level 
alone may not adequately predict pathological stage 
because the relationship between pathological stage 
a n d   s e r u m   P S A   v a r i e s   b y   t u m o r   g r a d e ,   v o l u m e ,   a n d  
site of origin (55-57). Nevertheless, comparative stu-
dies have demonstrated that PSA and its related test-
i n g   c a n   i n c r e a s e   t h e   d e t e c t i o n   r a t e   o f   p r o s t a t e   c a n c e r  
i n   m e n   w i t h   n o   s y m p t o m s   ( 3 1 ,   5 8 ) .   I t   h a s   a l s o   b e e n  
shown that the stage distribution of cancers detected 
through  PSA  screening  was  much  more  favorable 
than that which occurred in the population without 
PSA screening.  
S e r u m   P S A   t e s t i n g   i s   v i t a l   n o t   o n l y   i n   s c r e e n i n g  
a n d   e a r l y   d e t e c t i o n ,   b u t   i t   h a s   a l s o   b e e n   f o u n d   t o   b e  
essential in diagnosing localized prostate cancer. PSA 
testing  is  now  a  standard  application  clinically  for 
s t a g i n g   a n d   m o n i t o r i n g   p r o s t a t e   c a n c e r   ( 4 6 ) .   T h e  
prevalent acceptance of PSA screening has increased 
t h e   d i a g n o s e s   o f   p rostate cancer at an earlier stage and 
age (59) and has reduced the likelihood by half that a 
new case will be localized and by 33% that a new case 
will be metastatic. Furthermore, because PSA screen-
ing  has  become  routine,  the  occurrence  of  prostate 
c a n c e r   i n   m e n   o v e r   7 0   y e a r s   h a s   d e c l i n e d   ( 6 0 -62). 
However, despite a decrease in the incidence of pros-
tate  cancer  since 1992, an  apparent  increase  in  the 
prevalence has continued (63). The possible explana-
t i o n s   f o r   t h i s   m a y   b e   t h e   c o m b i n e d   e f f e c t s   o f   t h e   c o n-
t i n u o u s   r i s e   i n   t h e   l i f e   e x p e c t a n c y   o f   t h e   U S   p o p u l a-
tion (64) and the inclination toward  early  detection. 
Consequently, the prolonged lifespan and increased 
n u m b e r   o f   s u r v i v o r s   l i v i n g   w i t h   t h e   d i a g n o s i s   o f  
p r o s t a t e   c a n c e r   i s   l e a d i n g   t o   a n   i n c r e a s e   i n   t h e   c o s t   o f  
treating the disease (65).  
The  most  important  adverse  effect  of  prostate 
cancer screening is overdiagnosis and overtreatment 
(66). Overdiagnosis refers to detecting prostate cancer 
through  PSA  testing  that would  otherwise  not  have 
been  diagnosed  in  the  person’s  lifetime.  A  rando-
m i z e d   s t u d y   o f   s c r e e n i n g   f o r   p r o s t a t e   c a n c e r   w a s   i n-
itia t e d   i n   t h e   e a r l y   1 9 9 0 s   t o   a s s e s s   t h e   o u t c o m e   o f  
s c r e e n i n g   f o r   P S A   o n   d e a t h   r a t e s   f r o m   p r o s t a t e   c a n c e r .  
T h e   r e s e a r c h e r s   c o n c l u d e d   t h a t   P S A -based screening 
reduced the death rate from prostate cancer by 20%, 
but  the  screening  was  associated  with  an  increased 
risk  of  overdiagnosis  (67).  Previous  studies  had  al-
r e a d y   d e m o n s t r a t e d   t h a t   r i s k s   i n c u r r e d   b y   e i t h e r  
screening/diagnosis  (68,  69)  or  resulting  treatment 
(70-7 6 )   o f   p r o s t a t e   c a n c e r   w e r e   b o t h   s u b s t a n t i a l .   F u r-
ther study revealed that, for every patient who bene-
f i t s   f r o m   P S A   d i a g n o s i s -initiated  treatment,  47  pa-
tients  undergo  unnecessary  biopsy  and  other  treat-
ments because of false-positive PSA test results (67). 
After 7 to 10 years of follow-up, the rate of death from 
p r o s t a t e   c a n c e r   w a s   v e r y   l o w   a n d   d i d   n o t   d iffer  sig-
n i f i c a n t l y   b e t w e e n   t h e   t w o   g r o u p s   u s e d   i n   t h e   s t u d y .  
A l s o ,   p r o s t a t e   c a n c e r   s c r e e n i n g   o f f e r e d   n o   r e d u c t i o n  
in death rate after 7 years and no apparent indication 
o f   b e n e f i t   a m o n g   6 7 %   o f   t h e   s u b j e c t s   w h o   c o m p l e t e d  Journal of Cancer 2010, 1 
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10 years of follow-up (67). Although   P S A   t e s t i n g   a s   a  
reliable biomarker for prostate cancer diagnosis re-
mains controversial today, researchers have reported 
that overdiagnosis rates are about 29% for Whites and 
4 4 %   f o r   B l a c k s ,   s u g g e s t i n g   t h a t   m o s t   o f   t h e   c a n c e r s  
detected  through  PSA  testing  would  have  been  di-
agnosed  in  the  lifetime  of  the  patient  and  that  PSA 
screening detects mainly cancers with a high clinical 
consequence to patients (22). 
T h e   u s e   o f   P S A   f o r   p r o s t a t e   c a n c e r   s c r e e n i n g   h a s  
l e d   t o   a   g r e a t   i n c r e a s e   i n   t h e   n u m b e r   o f   m e n   u n d e r-
go i n g   T R U S   ( 7 7 ) ,   a   p r o c e d u r e   i n   w h i c h   a   p r o b e   t h a t  
sends out high-energy sound waves is inserted into 
the  rectum  against  the  prostate  gland  to  image  the 
e n t i r e   g l a n d   ( 2 ) .   A r e a s   o f   t h e   g l a n d   w i t h   v a r y i n g  
morphology frequently produce different images. The 
advantage of TRUS is its high sensitivity, and, thus, it 
p l a y s   a   v e r y   i m p o r t a n t   r o l e   i n   e a r l y   d e t e c t i o n .   B e s i d e s  
being a screening test, TRUS can also be used to guide 
needle biopsies of the prostate gland for diagnostic 
purposes (22). However, it has poor specificity when 
used as the sole screening for modality.  
Research conducted in the early 1990s revealed 
that  PSA  combined  with  DRE  is  the  most  effective 
screening  and  early  detection  modality  for  prostate 
cancer (32, 78-8 1 ) .   A s   s c r e e n i n g s   b e c a m e   m o r e   p r e v a-
lent, a study in the late 1980s concluded that the oc-
currence of prostate cancer significantly increased and 
that PSA testing was associated with the acceleration 
of  the  overall  occurrence  of  prostate  cancer  (81-84). 
Research  revealed  that  conducting  extensive  PSA 
testing led to a decline in the mortality rate while the 
r a t e   o f   i n c i d e n t   c a s e s   c o n t i n u e d   t o   r i s e   ( 8 5 -87). Some 
s t u d i e s   h a v e   c a s t   d o u b t s   o v e r   t h e   r e l a t i o n s h i p   b e-
tween the decline in prostate cancer mortality and the 
i n c r e a s e   o f   P S A   s c r e e n i n g   ( 8 8 -90).  This  controversy 
m a y   b e   p a r t l y   r e s u l t   f r o m   t h e   f a c t   t h a t   P S A   i s   m o r e  
p r o s t a t e   s p e c i f i c   t h a n   c a n c e r   s p e c i f i c ,   w h i c h   l e a d s   t o   a  
c o n s e q u e n t   i n c r e a s e   i n   t h e   r a t e   o f   f a l s e -positive results 
(91). 
Several  researchers  have  proposed  that,  before 
PSA testing was available, the decrease in death due 
t o   p r o s t a t e   c a n c e r   c o u l d   h a v e   r e s u l t e d   f r o m   t h e   i n-
c r e a s e   i n   e a r l y   d e t e c t i o n   w i t h   D R E ,   a s   s h o w n   b y   e a r-
l i e r   s t a g e   a t   d i a g n o s i s   a n d   b y   i n c r e a s i n g   r a t e s   o f   s u r-
gery for localized prostate cancer in the decade prior 
to the start of widespread PSA testing. Another poss-
ible  explanation  for  the  decrease  in  prostate  cancer 
mortality  is  that  the  tendency  to  classify  prostate 
cancer as the underlying cause of death has shifted 
(92). Some researchers have argued in the alternative 
that the survival rates that are specific to the stage of 
the cancer imply that the swift reduction in mortality 
followed by a large increase in incidence may be a 
r e s u l t   o f   t h e   l a r g e   a m o u n t   o f   h i g h -grade  prostate 
cancers detected before metastasis. Consequently, it is 
reasonable to consider the decrease in the incidence 
rate of advanced disease as predictive of a subsequent 
decrease in prostate cancer mortality rates rather than 
considering the trend in the context of the estimated 
average lead time gained (85). 
 The American Cancer Society National Prostate 
Cancer  Detection  Project  reported  that  5  years  fol-
lowing  an  annual  testing  by  PSA,  DRE,  and  TRUS, 
92% of cancers detected were localized to the prostate, 
compared to 66% in a contemporary national database 
covering  men  the  same  age  (93).  Prostate  cancer 
screening  appears  effective  when  one  considers  the 
population  mortality  trends  related  to  this  disease; 
p r o s t a t e   c a n c e r   m o r t a l i t y   b e g a n   t o   d e c l i n e   i n   t h e  
United States after several years of steadily growing 
death rates (94). Several reports have argued that PSA 
t e s t i n g   m a y   n o t   t o   b e   r e s p o n s i b l e   f o r   r e d u c e d   m o r t a l-
ity  observed  within  the  first  10  years  following  the 
onset  of  widespread  the  testing  (95).  Some  studies 
c o m p a r e d   t h e   e f f i c i e n c y   o f   P S A   t e s t i n g   a l one  or  in 
combination with DRE and TRUS. As discussed ear-
lier,  despite  any  conclusive  evidence  showing  that 
screening asymptomatic men and treating those with 
early  stage  disease  improved  survival,  serum  PSA 
screening  has  been  generally  accepted  and  still  re-
mains as a commonly used diagnostic biomarker for 
p r o s t a t e   c a n c e r   ( 9 6 ) .   F u r t h e r m o r e ,   a l t h o u g h   o v e r-
d i a g n o s i s   m a y   r e s u l t   f r o m   p r o s t a t e   c a n c e r   s c r e e n i n g ,  
m o s t   o f   t h e   r i s k   o c c u r s   i n   m e n   i n   w h o m   t h e   c a n c e r  
w o u l d   n o t   h a v e   b e e n   d e t e c t e d   i f   t h e y   h a d   n o t   b e e n  
screened (67).  
4. CRITERIA FOR SELECTING/ 
IDENTIFYING PROSTATE CANCER 
BIOMARKERS 
Criteria as a biomarker 
A   b i o m a r k e r   m u s t   b e   s h o w n   t o   c o r r e l a t e   w i t h   a n  
interested outcome, such as disease progression, re-
c u r r e n c e ,   o r   s u r v i v a l ,   i f   i t   i s   t o   b e   s e e n   a s   u s e f u l   f o r 
diagnosing and monitoring a disease. Several analys-
es  with  different  variables  should  demonstrate  that 
t h e   b i o m a r k e r   c o u l d   p r e d i c t   t h e   r e l e v a n t   s t a g e   o r  
grade  irrespective  of  the  characteristics  frequently 
accessible. For statistical implication to be assessed, 
t h e s e   t e s t s   o u g h t   t o   b e   p e r f o r m e d   o n   a   s e t   o f   c a s e s  
with adequate ending data and at a sufficient number 
of incidents. With the help of tissue microarrays, this 
process is becoming significantly more efficient (97). 
The selection of a biomarker shou l d   h a v e   a   b i o-
l o g i c a l   o r   t h e r a p e u t i c   b a s i s   o r ,   a t   m i n i m u m ,   t h e   b i o-
marker should indicate a reliable correlation with the Journal of Cancer 2010, 1 
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presence,  characteristics,  or  aggressiveness  of  the 
c a n c e r .   A l s o ,   t h e r e   s h o u l d   b e   a n   e v a l u a t i o n   o f   t h e  
strength of the marker in relation to the outcome of 
the disease, which, together with other factors, should 
be carried out as an independent predictor in a mul-
tivariable assay (98). An ideal biomarker should be 
quick, consistent, economical, and quantifiable in an 
accessible  biological  fluid  or  clinical  sample  (e.g., 
plasma, urine, or prostatic fluid) that is readily inter-
pretable by a clinician (99, 100) (Fig. 1). Its expression 
should be significantly increased (or decreased) in the 
r e l a t e d   d i s e a s e   c o n d i t i o n ,   a n d   n o   o v e r l a p   s h o u l d   e x i s t 
i n   t h e   l e v e l s   o f   b i o m a r k e r   b e t w e e n   h e a l t h y   c o n t r o l  
subjects and untreated patients. 
I n   t h e   g e n e r a l   p o p u l a t i o n ,   t h e   l e v e l s   o f   b i o-
m a r k e r   s h o u l d   n o t   v a r y   w i d e l y   s o   t h a t   t h e   s e v e r i t y  
a n d   p r o g n o s i s   o f   t h e   d i s e a s e   c a n   b e   p r e d i c t e d   b a s e d  
on large deviations of the biomarker from the refer-
e n c e   v a l u e s   i n   t h e   c o n t r o l   p o p u l a t i o n   ( 9 8 ,   1 0 1 ) .   F u r-
thermore,  within  the  general  population,  the  abun-
d a n c e   o r   a c t i v i t y   o f   a n   i d e a l   b i o m a r k e r   s h o u l d   b e  
similar in subjects (99). In this way, it provides a great 
advantage  for  clinical  diagnosis  and  monitoring  of 
disease activity. It would also provide a correlation 
between subjects with a disease and those with other 
d e a d l y   c o n d i t i o n s   o c c u r r i n g   i n   t h e   c o n t e x t   o f   a   p a r-
t i c u l a r   d i s e a s e   f o r   w h i c h   t h e   b i o m a r k e r   w i l l   b e   e x-
amined (98, 99). One critical factor that determines the 
selection of a candidate biomarker is the caliber of 
scientific and clinical results such as (i) linking the 
g e n e   o r   p r o t e i n   f u n c t i o n   t o   t h e   b i o l o g y   o f   t h e   d i s e a s e ,  
( i i )   r e l a t i n g   t h e   c a n d i d a t e   b i o m a r k e r   t o   t h e   p r e s ence of 
the disease, (iii) variations in stage, (iv) reaction to 
therapy,  and  (v)  overall  survival;  all  of  which  will 
back the possible efficacy of the candidate biomarker. 
F o r   p r o s t a t e   c a n c e r   b i o m a r k e r s   u s e d   i n   e a r l y   d e t e c t i o n  
or monitoring of disease, the model candidate should 
be prostate specific and able to differentiate between 
normal BPH, prostatic intraepithelial neoplasia, and 
cancerous prostate tissues (100). 
Validation of biomarker  
Biomarkers are essential factors in clinical and 
biological research. Identifying a new candidate bio-
marker is followed by a thorough operational evalua-
tion to validate its application in the clinical setting 
( 9 9 ) .   B i o m a r k e r s   t h a t   h a v e   b e e n   s c i e n t i f i c a l l y   s c r u t i-
n i z e d   m u s t   p a s s   s e v e r a l   p r o p o s e d   p r a c t i c a l   t e s t s   p r i o r  
to being accepted for clinical practice. Five conceptual 
phases  of  biomarker  development  have  been  sug-
gested (102-103): (i) preclinical exploratory, (ii) clinical 
assay and validation, (iii) retrospective longitudinal, 
(iv) prospective screening, and (v) cancer control.  
The first step involves identifying the biomarker 
and  evaluating  it  for  a  specific  clinical  indication. 
P r i o r   t o   s u b m i t t i n g   i t   f o r   U S   F o o d   a n d   D r u g   A d m i n-
istration (FDA) approval, analytical and clinical con-
f i r m a t i o n   m u s t   b e   c a r r i e d   o u t   ( F i g .   2 ). Alternatively, if 
t h e   m a r k e r   i s   i n t e n d e d   s o l e l y   f o r   r e s e a r c h ,   i t   m a y   n o t  
require  FDA  approval. After approval  by  the  FDA, 
the Center for Medicaid and Medicare Services (CMS) 
m i g h t   c o n c l u d e   t h a t   t h e   b i o m a r k e r   i s   e s s e n t i a l   f o r  
improving patient care (104). However, a number of 
challenges are involved in the process, and the major-
i t y   o f   c a n d i d a t e   m a r k e r s   a r e   s t i l l   i n   t h e   p r e m a t u r e  
phases of development. Thus far, clinical studies are 
usually reflective, and the few promising studies that 
have been conducted have frequently produced con-
flicting results (104). 
 
Fig. 1 Characteristics of an Ideal Biomarker Journal of Cancer 2010, 1 
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Fig. 2. Steps involved in the validation of a biomarker. The initial step involves identifying the biomarker, followed by 
assessing its relevance to the particular information sought. A diagnostic validation for its clinical use is done, and, if the 
results are positive, it is submitted to the FDA for approval. If approval is denied, it may go back to the lab to be used in 
research as an analyte-specific reagent. An approval, on the other hand, p a v e s   t h e   w a y   f o r   i t   t o   go to the Center for Medicaid 
and Medicare Services (CMS). It may go directly to the CMS and boycott the FDA if it is for research purposes only [104]. 
 
5. BIOMARKERS FOR THE DIAGNOSIS 
AND PROGNOSIS OF PROSTATE 
CANCER  
As described earlier, a biomarker is in general an 
analyte that signifies the presence and/or degree of a 
biological  process,  which  in  itself  is  frequently  di-
rectly linked to the clinical expressions and result of a 
p a r t i c u l a r   d i s e a s e   ( 9 9 ) .   B i o m a r k e r s   h a v e   b e e n   s h o w n  
to possess many important applications including use 
as a diagnostic tool to identify patients with a disease 
or abnormal condition, a tool for staging disease or 
c l a s s i f y i n g   t h e   e x t e n t   o f   d i s e a s e ,   a n   i n d i c a t o r   o f   d i s-
ease  prognosis,  and  for  predicting  and  monitoring 
clinical response to an intervention (105). Cancer early 
detection  markers indicate  the  presence  of  an  early 
cancer  or  t h a t   c a n c e r   w i l l   o c c u r   w i t h   n e a r l y   1 0 0 %  
certainty within a very short time interval. This is in 
contrast to screening markers (22). Biomarkers for the 
diagnosis  and  prognosis  of  prostate  cancer  include 
DNA-based  markers,  RNA-based  biomarkers,  and 
protein markers (see Fig. 3 for examples).  
A   l o t   o f   t h e   b i o m a r k e r s   u s e d   c u r r e n t l y   w e r e  
discovered unexpectedly while others were detected 
through the use of basic reasoning with understand-
ing of the fundamental biochemical defect. Biomark-
ers are used to observe th e   n a t u r a l   c o u r s e   o f   t h e   c o n-
dition  and  to  assess  the  effectiveness  of  treatments. 
A l s o ,   t h e y   m a y   h e l p   i n   t h e   d e v e l o p m e n t   o f   s e t   t h e r a-
peutic  objectives,  thereby  presenting  standards  for 
judging  success  in  the  management  of  chronic  dis-
e a s e s   ( 9 9 ) .   F o r   s o m e   t i me, biomarkers have served as 
a n   i n d i c a t o r   o f   t h e   p r e s e n c e   o f   a   p a r t i c u l a r   d i s e a s e   a n d  
reflected the activity of a given condition either dur-
i n g   i t s   n a t u r a l   c o u r s e   o r   i n   r e s p o n s e   t o   a   g i v e n   t h e r a-
peutic  intervention.  In  addition,  they  may  be  useful 
for prognostic purposes in the outcome of diseases, 
with  particular  attention  on  the  quantitative  bio-
markers  that  demonstrate  a  relationship  with  the 
clinical manifestation of the disease and that have an Journal of Cancer 2010, 1 
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e f f e c t   o n   q u a l i t y   o f   l i f e ,   r i s k   o f   c o m p l i c a t i o n s ,   o r   s u r-
vival. Surrogate biomarkers have a significant func-
tion  in  disease  monitoring after  accepted  treatments 
are introduced. Surrogates are particularly important 
f o r   t h o s e   t r e a t m e n t s   t h a t   a r e   u n c o m m o n ,   s u c h   a s   c a s e s  
i n   w h i c h   t h e   d i r e c t   s t u d y   h a s   p r o v e d   t o   b e   v e r y  diffi-
c u l t   b e c a u s e   o f   t h e   l i m i t e d   n u m b e r   o f   p a t i e n t s   a n d  
varying expression of their primary illness or in which 
the  efficiency  of  the  treatment  must  justify  the  high 
cost (99).  
 
Fig. 3. A general classification of biomarkers based on their description [104]. 
 
T h e   m a n a g e m e n t   o f   p r o s t a t e   c a n c e r   h a s   u n d e r-
g o n e   s e v e r a l   d r a m a t i c   c h a n g e s   a s   a   r e s u l t   o f   t h e   e v o-
lution of biomarkers used in screening, detecting, and 
predicting  the  disease  (106,  107).  Human  prostatic 
acid phosphatase (PAP) (or serum acid phosphatase 
(AP)  was  reportedly  the  first  serum  biomarker  for 
p r o s t a t e   c a n c e r .   G u t m a n   a n d   h i s   c o l l e a g u e s   o b s e r v e d  
in the 1930s that patients with prostate cancer metas-
tasized to bone had elevated levels of PAP activity at 
t h e   s i t e   o f   m e t a s t a s i s   a n d   h i g h   s e r u m   l e v e l s   o f   t h e  
protein (108-110). This finding effectively established 
the value of serum acid phosphatase activity as an aid 
in  diagnosing  metastatic  carcinoma  of  the  prostate 
a n d   c o n s e q u e n t l y   a s   a   b i o m arker for prostate cancer 
progression  and  reaction  to  androgen  deprivation 
therapy of prostate cancer that had metastasized (97, 
1 1 0 ) .   T h e   t o t a l   s e r u m   A P   c o m p r i s e s   a   m i x t u r e   o f  
phosphatases  from  most  tissues  of  the  body  (111). 
M e n   w i t h   h i g h   p r e o p e r a t i v e   P A P   h a d   a   g r e a t e r   c h a n c e  
of developing lymph-node-positive disease and me-
tastases than did their counterparts with normal PAP 
(112). Posttreatment PAP, as determined by other re-
searchers,  could  predict  outcome  when  combined 
with other clinical factors (113).  
 Although  AP,  with  an  elevated  level  in  more 
t h a n   7 0 %   o f   p a t i e n t s   ( 1 1 4 ) ,   w a s   l i n k e d   e a r l y   w i t h  
prostate cancer that had spread, both AP and pros-
tate-s p e c i f i c   A P   ( P A P ,   i t s   s u b t y p e )   a r e   n o t   s e n s i t i v e  
enough for screening. Patients with localized cancer 
frequently display normal levels, and neither PAP nor 
AP show sufficient sensitivity to be used as a reliable 
biomarker  for  recurrence  or  response  to  systemic 
t h e r a p y .   S u d d e n   v a r i a t i o n s   i n   P A P   a n d   A P   h a v e   b e e n  
observed, which has led to questioning whether this 
enzyme is a legitimate biomarker in cancer diagnosis. 
F u r t h e r m o r e ,   t h e   u s e   o f   A C P   h a s   b e e n   r e d u c e d   b e-
c a u s e   o f   t h e   d e v e l o p m e n t   o f   P S A   s c r e e n i n g ,   w h i c h   i s   a  
more sensitive and specific tumor marker (22). 
PSA  was  later  discovered  as  a  biomarker  for 
prostate   c a n c e r   f o l l o w i n g   t h e   d i s c o v e r y   o f   s e r u m   P A P .  
T h e   P S A   t e s t   w a s   f i r s t   u s e d   i n   t h e   f i e l d   o f   f o r e n s i c  
science as a marker for human semen (41), and it was 
first purified in the late 1970s from prostate extracts 
(43).  Later  studies  established  that  PSA  could  be 
quantified in serum, and its serum levels were high in 
m e n   w i t h   p r o s t a t e   c a n c e r   ( 4 4 ) .   T h e   p r o s t a t e   g l a n d  
p r o d u c e s   P S A ,   a n d   t h e   t e s t   m e a s u r e s   P S A   l e v e l s   i n   t h e  
b l o o d   ( s e r u m ) .   B e c a u s e   P S A   i s   f r o m   t h e   b o d y   a n d   c a n  
be used in disease detection, it is often referred to as a 
b i o l o g i c a l   m a r k e r   o r   a   t u m o r   m a r k e r .   B o t h   p r o s t a t e  
cancer and benign prostatic conditions (e.g., BPH) can 
increase  PSA  le v e l s   f r o m   a   n o r m a l l y   l o w   l e v e l   t o   a n  
elevated state in the blood (2). PSA can be present in a 
f r e e   f o r m   o r   c o m p l e x e d   w i t h   α 1 -antichymotrypsin or Journal of Cancer 2010, 1 
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α2-macroglobulin in circulation (115). Patients with 
c a n c e r   c a n   b e   d i s t i n g u i s h e d   f r o m   t h o s e   w i t h   B P H  
based  on  the  percentage  of  free  to  total  PSA  in  the 
serum. For those with an elevated level of PSA, par-
t i c u l a r l y   w i t h   a   P S A   r a n g e   b e t w e e n   4   a n d   1 0   n g / m l ,  
patients are more likely to have prostate cancer when 
t h e   f r e e   P S A   i s   l e s s   t h a n   2 0 -2 5 %   o f   t h e   t o t a l   s e r u m   P S A  
le v e l .   P r o P S A ,   t h e   p r e c u r s o r   f o r m   o f   P S A ,   m a y   s e r v e  
as an additional indicator in differentiating cancers 
from benign processes (22). Moreover, in a group of 
patients examined with PSA levels between 2.5 and 4 
n g / m l ,   t h e   r a t i o   o f   p r o P S A   t o   f r e e   P S A   s h o w e d   m ore 
specificity in detecting cancers when compared to the 
detection rate by free PSA alone (116).  
Serum PSA was initially used for screening men 
with an existing diagnosis of prostate cancer (117) and 
was regarded as an ideal marker for identifying re-
curring disease subsequent to treatment. The fact that 
levels of serum PSA remained undetectable demon-
strated the absence of recurrent disease among men 
who  underwent  radical  prostatectomy  (118).  PSA 
gradually replaced serum PAP, which was considered 
inferior t o   P S A ,   f o r   p r o s t a t e   c a n c e r   s c r e e n i n g ,   s t a g i n g ,  
a n d   p r o g n o s t i c a t i o n   ( 1 1 9 ) .   H o w e v e r ,   P A P   i s   o n c e  
again attracting some attention because of the fact that 
s e v e r a l   s t u d i e s   h a v e   s h o w n   t h a t   i t   i s   a   g o o d   p r o g n o s-
t i c   m a r k e r   f o r   p a t i e n t s   w i t h   a g g r e s s i v e   d i s e a s e   w h o  
went through local therapy and are at high risk for 
distant relapse (120). However, PAP has no role as a 
diagnostic screening tool (22). 
In 1994, PSA was officially approved for prostate 
c a n c e r   s c r e e n i n g   b y   t h e   F D A ,   a n d   4 . 0   n g / m l   w a s   s e t  
as the upper limit   o f   n o r m a l   range  (see time line in 
Fig. 4). Following its prevalent use for identifying the 
i n c i d e n c e   o f   p r o s t a t e   c a n c e r ,   P S A   b e c a m e ,   a n d   i s   s t i l l ,  
the most frequent method of detecting prostate cancer 
and  has  resulted  in  a  considerable  stage  migration. 
Th e   o b s e r v e d   d e c l i n e   i n   m o r t a l i t y   r a t e   b o t h   i n   t h e  
United States and around the world has been partially 
a t t r i b u t e d   t o   t h e   o n g o i n g   s c r e e n i n g   b a s e d   o n   P S A  
levels (121). However, there are still some significant 
controversies  over  PSA screening  because  no  study 
has  successfully  shown  any  significant  correlation 
between  such  screening  and  a  decline  in  mortality 
rate. Further research has facilitated significant mod-
ification in using and understanding serum PSA, de-
s p i t e   t h e   l a c k   o f   d i r e c t   e v i d e n c e .   P S A   i s   u s e f u l   not 
o n l y   f o r   d e t e c t i n g   p r o s t a t e   c a n c e r   b u t   a l s o   f o r   d r a w i n g  
a parallel between its levels at diagnosis and more 
advanced stages (122).  
 
 
 
 
 
 
Fig. 4 Timeline for Early Prostate Cancer Biomarkers for Diagnosis 
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Several clinicians currently use a threshold range 
of  2.5–3 . 0   n g / m l   f o r   p r o p o s i n g   p r o s t a t e   b i o p s y ,   b e-
c a u s e   t h e   p r o g n o s i s   o f   p r o s t a t e   c a n c e r   i s   b e t t e r   w h e n  
the  disease  is  identified  at  lower  PSA  levels  (123). 
However, limitations in the use of PSA for screening 
prostate cancer are becoming noticeable. Many men, 
as they grow older, suffer from various nonmalignant 
processes,  including  BPH  and  prostatitis  that  often 
l e a d   t o   s e r u m   P S A   i n c r e a s e   t h a t   r e s u l t s   i n   a   l i m i t e d  
spec i f i c i t y   o f   P S A   t e s t i n g   f o r   c a n c e r   d e t e c t i o n   ( 1 0 5 ) .  
O n   t h e   c o n t r a r y ,   t h e   h i g h   l e v e l s   o f   P S A   c a n   b e   m u d-
d l e d   u p   b y   c e r t a i n   a l t e r a t i o n s   i n   t h e   p r o s t a t e   a n d   b y  
clinical procedures. Overall, an increase in the levels 
of PSA is not as specific as it is sensitive for  prostate 
c a n c e r   d i a g n o s i s .   A c c o r d i n g   t o   T h o m p s o n   e t   a l . ,  
p r o s t a t e   c a n c e r   h a s   b e e n   d e t e c t e d   i n   a b o u t   1 5 %   o f   m e n  
w i t h   n o r m a l   o r   v e r y   l o w   l e v e l s   o f   t o t a l   P S A ,   t h e r e b y  
making it difficult to reliably rule out the possibility of 
cancer at any PSA level (124). This has resulted in a 
c a l l   f o r   r e e v a l u a t i n g   t h e   a p p r o a c h   t o   d i a g n o s e   p r o s-
t a t e   c a n c e r   a n d   a   s e a r c h   f o r   n e w   p r o s t a t e   c a n c e r   b i o-
markers (46, 124-127).  
6. CANDIDATE MARKERS FOR 
PROSTATE CANCER 
One  of  the  established  objectives  of  cancer  re-
search is to identify  the  molecular  mechanisms  that 
dictate the initiation and progression of the disease 
and then to ascertain those molecular markers asso-
c i a t e d   w i t h   t h e   c a n c e r   t o   t a r g e t   c a n c e r   c e l l s   w i t h   s p e-
cifically designed drugs. Like all respective biomark-
ers  correlated  to  their  respective  cancers,  prostate 
biomarkers exhibit some or all of these abilities: detect 
t h e   p r e s e n c e   o f   p r o s t a t e   c a n c e r ,   m o n i t o r   a n d   r e l a y   i t s  
progression, prognosticate the possibility of a recur-
rence,  predict  the  response  to  therapy,  and  foresee 
whether the patient will be disease-free and survive. 
C l i n i c i a n s   r e l y   o n   b i o m a r k e r s   t o   d e t e c t   c a n c e r   a t  
p r e m a t u r e   s t a g e s   o r   p r i o r   t o   t u m o r   m e t a s t a s i s ,   w h e n  
the efficacy of therapeutic drugs is greater. 
The need for effective prostate cancer biomark-
ers is therefore urgent and great, and the search for 
t h e m   h a s   b e e n   a   p r i o r i t y   o f   r e s e a r c h e r s   f o r   y e a r s .   I n  
t h e   l a s t   d e c a d e ,   P S A   h a s   b e e n   w i d e l y   u s e d   a s   a   u s e f u l  
t o o l   f o r   s c r e e n i n g   p r o s t a t e   c a n c e r .   H o w e v e r ,   P S A   a n d  
o t h e r   e s t a b l i s h e d   b i o m a r k e r s   a r e   s t i l l   n o t   i d e a l ,   a s   t h e y  
lack diagnostic specificity and prognostic value and 
l e a d   t o   a   h i g h   r a t e   o f   f a l s e -positives. Consequently, 
t h e   l a c k   o f   s p e c i f i c   a n d   s e n s i t i v e   b i o m a r k e r s   f o r   e a r l y  
detection  of  prostate  cancer  calls  for  investigating 
novel and existing biomarkers and developing new 
approaches  to  identify  and  validate  more  accurate 
diagnostic  and  prognostic  biomarkers  for  prostate 
cancer.  
Current advancements in proteomics, tissue mi-
croarray,  DNA  microarray,  immunohistochemical 
staining,  and  other  biotechnologies  have  paved  the 
w a y   a n d   h a v e   s i g n i f i c a n t l y   i n c r e a s e d   t h e   p a c e   a t  
which  novel  biomarkers  are  being  discovered  and 
developed.  Using  these  methodologies,  researchers 
h a v e   r e p o r t e d   s e v e r a l   b i o m a r k e r s   w i t h   g r e a t   p o t e n-
tial, and they are currently undergoing further inves-
tigation for validation. Although the existing method 
of  discovery  usually  identifies  several  candidate 
markers in each investigation, only a few of them ever 
make it through clinical validation. 
We will discuss and list (Table 4) some of the 
biomarkers that have a substantial amount of sup-
portive data that are biologically and clinically per-
s u a s i v e   f o r   t h e m   t o   b e   f u r t h e r   d e v e l o p e d   a n d   o t h e r  
potential candidates still being investigated. A few of 
the recent candidates that have generated some ex-
c i t e m e n t   f o r   t h e i r   p o t e n t i a l   a s   b i o m a r k e r s   f o r   p r o s t a t e  
cancer are also discussed. Needless to say, this list is 
b y   n o   m e a n s   e x h a u s t i v e ,   a n d   i t   w i l l   k e e p   g r o w i n g  
with the help of the advance of newer/better tech-
nologies in molecular analysis. 
 
Table 4. Description of the Biological Function of Selected Serum Markers 
Serum Marker  Description/Type  Biological Function  Purpose 
Chromogranin-A  Pro-hormone peptide released by 
neuroendocrine cells 
Uncertain definite function. Possesses calcium-binding abilities 
and may act through paracrine and autocrine manners.  
Prognosis 
Neuron-specific eno-
lase 
Isomer of the glycolytic enzyme 
2-phospho-D-glycerate hydrolase 
released by neuroendocrine cells 
Uncertain definite function. Possibly serves as paracrine and 
autocrine factor. 
Prognosis 
Human kallikrein 2  Serine protease with trypsin-like 
substrate specificity 
Splits pro-PSA to create PSA  Diagnosis 
Urokinase-type plas-
minogen activator 
system 
Serine protease and transmem-
brane receptors 
Converts plasminogen to plasmin  Diagnosis 
(fragments) and 
prognosis 
Interleukin-6  Cytokine  Implicated in hematopoiesis and the immune response 
through mediation of B-cell differentiation and the acute-phase 
inflammatory response 
Prognosis 
Transforming growth 
factor-β 
Cytokine  Involved in cellular proliferation, cellular chemotaxis, cellular 
differentiation, angiogenesis, humoral immunity, 
cell-mediated immunity, and wound healing 
Prognosis Journal of Cancer 2010, 1 
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Prostate mem-
brane-specific antigen 
Type II integral membrane glyco-
protein with cell surface carbox-
ypeptidase function 
Possesses folate hydrolase function. Also is involved in the cell 
stress reaction, signal transduction, cell migration, and nutrient 
uptake. May possess questionable receptor function. 
Diagnosis 
Prostate-specific cell 
antigen 
Glycosyl phosphatidylinosi-
tol-anchored cell surface glyco-
protein 
Known cell surface marker. Perhaps involved in several stem 
cell activities involving proliferation or signal transduction. 
Prognosis 
α-Methylacyl-CoA 
racemase (autoantibo-
dies) 
Peroxisomal and mitochondrial 
racemase 
Engaged in bile acid synthesis, stereoisomerization, and 
β-oxidation of branched-chain fatty acids 
Diagnosis 
Early prostate cell 
antigen-1, -2 
Nuclear matrix protein  May be involved in early prostate carcinogenesis; however, has 
uncertain contribution to nuclear morphology  
Diagnosis 
GSTP1 hypermethyla-
tion 
CpG island hypermethylation of 
DNA encoding the protein, glu-
tathione S-transferase π 
Hypermethylation of GSTP1 inhibits transcription. GSTP1 
usually acts by conjugation of oxidant and electrophilic   car-
cinogens to glutathione to inactivate them 
Diagnosis 
Testosterone  Steroid hormone  Acts in the natural growth and support of the prostate gland 
and seminal vesicles.   M a n y   a c t i o n s   o n   s e x u a l   d e v e l o p m e n t   a n d  
anabolism. Also involved in endocrine signal transduction. 
Prognosis 
Estrogen  Steroid hormone  Many effects on female sexual development. Also acts in the 
control of sperm development and in endocrine signal trans-
duction. 
Prognosis 
Sex hormone-binding 
globulin 
Serum glycoprotein-binding pro-
tein 
Adheres to and carries testosterone and estradiol. Also in-
volved in endocrine signal transduction. 
Prognosis 
Caveolin-1  Integral membrane protein  Works to regulate cholesterol metabolism and cellular trans-
formation and is engaged in transducing cell-to-cell signals 
Prognosis 
E-cadherin  Calcium-dependent cell adhesion 
protein 
Plays major role as a cellular adhesion molecule in cell-to-cell 
adhesion of secretory tissues 
Prognosis 
β-Catenin  Adhesion protein (80-kDa frag-
ment isolated in prostate cancer) 
Aggregates with cadherin to regulate the formation of adhe-
rent junctions between cells 
Prognosis 
MMP-9  Zinc-dependent endogenous pro-
tease 
Acts in cell migration through and degradation of the ECM 
and in cell-cell adhesion. 
Prognosis 
Tissue inhibitor of 
MMPs (TIMP 1, 2) 
Protease inhibitor  Prevents synthesis of ECM   Prognosis 
Hepatocyte growth 
factor 
Polypeptide growth factor (secre-
tory protein of fibroblasts) 
A cellular growth, motility, and morphogenic factor. Also, 
involved in cell scattering and angiogenesis.  
Diagnosis/ 
prognosis 
MIC-1  Cytokine (TGF-β superfamily)  Uncertain role, but may induce apoptosis  Diagnosis/ 
prognosis 
Cytokine macrophage 
MIF 
Cytokine (secreted by lympho-
cytes) 
Modulates inflammation and the immune response. Activates 
cellular proliferation and angiogenesis, while inhibiting some 
tumor-suppressor genes. 
Diagnosis 
hK11  Serine protease (human kallikrein 
superfamily) 
Has an uncertain function. Acts like trypsin but, depending on 
the tissue or body compartment in which it is present, may 
possibly have many different functions. 
Diagnosis 
Progastrin-releasing 
peptide (ProGRP 
31–98) 
Neuropeptide  Split to form GRP. GRP acts in the regulation of metabolism, 
behavior, smooth muscle activity, some exocrine and endo-
crine operations, and cellular chemotaxis. 
Prognosis 
Apolipoprotein A-II 
(8.9 kDa isoform) 
Lipoprotein (abundant in HDL)  Effects plasma free fatty acid levels via operating in lipid me-
tabolism and transport 
Diagnosis 
50.8-kDa protein  Unknown, identified by mass 
spectrometry 
Uncertain function but possibly is parallel to the action of 
vitamin D-binding protein 
Diagnosis 
ILGF-1, -2  Growth hormone-dependent po-
lypeptides 
In the prostate gland, both modulate cellular proliferation, 
differentiation, and apoptosis. Also, acts in endocrine signal 
transduction.  
Diagnosis 
Leptin  Adipocyte-derived peptide  In metabolism, modulates hunger, energy use, and fat meta-
bolism and is also known to induce angiogenesis 
Diagnosis 
Endoglin (CD105)  Homodimeric transmembrane 
glycoprotein 
Controls TGF-β superfamily signaling pathway and therefore 
subsequently affects angiogenesis, cellular propagation, 
apoptosis, cell adhesion, and cell movement 
Prognosis 
EGFR family (c-erbB-1 
(EGFR), c-erbB-2 
(HER2/neu), c-erbB-3 
(HER3) and c-erbB-4 
(HER4)) 
Transmembrane glycoprotein 
receptors 
Transduce signals for multiple growth factors  Diagnosis and 
prognosis 
TSP-1  Homotrimeric extracellular matrix 
glycoprotein 
Inhibits angiogenesis by inhibiting cell development, move-
ment, and propagation and is also an effector molecule for the 
tumor suppressor gene p53 
Diagnosis 
VEGF  Dimeric, heparin-binding protein  An important endothelial cell growth factor that controls an-
giogenesis and augments vascular permeability  
Prognosis 
Huntingtin-interacting 
protein 1 (autoantibo-
dies) 
Cytoplasmic clathrin-binding 
protein 
Acts in growth factor receptor transport. Also, transforms 
fibroblasts by lengthening the half-life of growth factor recep-
tors.  
Diagnosis 
Prostasome (autoanti-
bodies) 
Prostatic secretory granules and 
vesicles composed of a lipid bi-
layer membrane and composite 
protein content 
Consist of proteins that act in numerous enzymatic reactions, 
transport, structure, GTP activity, molecular chaperoning, and 
signal transduction 
Diagnosis 
ZAG  Glycoprotein  Induces lipid decline in adipocytes and therefore is implicated 
as possibly acting in cachexia 
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CGRP  Neuropeptide  Vasodilatation and possibly regulation of protease secretion  Prognosis 
PSP94  Nonglycosylated secretory pep-
tide 
In all probability acts as a growth and calcium regulator, 
apoptosis inducer, and an inhibitor of FSH. 
Diagnosis 
Other methylated 
genes including 
RASSF1α, APC, 
RARB2 and CDH1 
Hypermethylated DNA encoding 
for various peptides 
Hypermethylation predictably inactivates gene transcription  Diagnosis 
Adapted from reference (159). 
 
α-Methylacyl Coenzyme A Racemase (AMACR) 
AMACR is an enzyme localized to the peroxi-
some and involved in fat metabolism and has been 
i d e n t i f i e d   t o   f u n c t i o n   a s   a   g r o w t h   p r o m o t e r ,   i n d e-
pendent of androgens, in prostate cancer (128, 129). 
By using various experimental methods and different 
prostate cancer specimens, the AMACR gene has been 
shown to be overexpressed in prostate cancer tissue at 
the mRNA and protein levels and making it a highly 
specific tissue biomarker currently used to aid in the 
pathological diagnosis (130-132). 
 AMACR has been reported to be involved in the 
crucial  role  in  peroxisomal  β−oxidation of branched 
chain fatty acid molecules (133). When prostate cancer 
t i s s u e s   w e r e   c o m p a r e d   w i t h   n o r m a l   c o n t r o l s ,   a   9 -fold 
i n c r e a s e   i n   m R N A   l e v e l s   o f   A M A C R   w a s   d i s c o v e r e d  
in 88% of the sample prostate cancer tissues (134). 
This finding h a s   p r o m p t e d   o t h e r   r e s e a r c h e r s   t o   p r o-
pose the possibility of analyzing the levels of AMACR 
from  urine  to  detect  prostate  cancer  (134).  Another 
potential use of AMACR includes analyzing and in-
terpreting specimens of prostate needle biopsy (and 
results)  that  are  usually  diagnostically  challenging 
(131).  Immunodetectable  serum  autoantibodies  gen-
e r a t e d   i n   r e s p o n s e   t o   t h e   A M A C R   t u m o r -associated 
antigen may also be useful in preliminary diagnosis, 
especially if combined with PSA screening. A consi-
derably more enhanced sensitivity and specificity in 
prostate  cancer  patients  with  mid-range  PSA  levels 
have  been  observed  with  AMACR  antibodies  than 
that with PSA. This demonstrates that AMACR can be 
useful in discriminating control subjects from those 
with prostate cancer (135). 
 S o m e   o f   t h e   l i m i t a t i o n s   o f   A M A C R   a s   a   b i o-
m a r k e r   i n c l u d e   t h e   p o s s i b i l i t y   o f   h u m o r a l   r e s p o n s e  
and production of endogenous AMACR antibody as a 
result of certain cancers other than prostate in patients 
s u f f e r i n g   f r o m   a u t o i m m u n e   d i s e a s e s   ( 9 7 ) .   I n   a ddition, 
A M A C R   l e v e l s   h a v e   a l s o   b e e n   o b s e r v e d   t o   b e   c o m-
monly  increased  in  patients  with  other  urological 
disorders like BPH. However, the diagnostic capabil-
ity  for  characterizing  organ-confined and metastatic 
p r o s t a t e   c a n c e r   w a s   i n c r e a s e d   b y   a d d i n g   t h e   A M A CR 
t e s t   t o   s e r u m   P S A   t e s t i n g   ( 1 3 6 ) .   T h e r e f o r e ,   a   n e w  
promising and noninvasive screening test for prostate 
cancer is to use quantitative reverse transcriptase po-
lymerase chain reaction (RT-PCR) to identify the ratio 
of  AMACR-to-PSA  transcript  (129).  Nevertheless, 
f u r t h e r   t e s t i n g   i s   u n d e r   w a y   t o   a s s e s s   a n d   p o s s i b l y  
validate the prospective use of this serum biomarker. 
Glutathione S-transferase P1 (GSTP1) 
Glutathione  S-transferase π is an example of a 
biomarker that has been extensively studied in pros-
tate cancer, primarily as a tissue marker. GSTs are a 
ubiquitous  family  of  multifunctional  enzymes  that 
conjugate  reactive  substrates  with  reduced  gluta-
thione (GSH) and are involved in detoxification (137, 
138). Their role in protecting the cells from oxidative 
attack  (137),  and  thereby  being  upregulated  in  the 
presence of free radicals, makes them a prime candi-
date  for  consideration  as  a  cancer  biomarker.  The 
GSTP1 gene has been observed to be unmethylated in 
a l l   n o r m a l   h u m a n   t i s s u e s   a n d   B P H ,   b u t   h y p e r m e t h y-
lated  in  specimens  of  prostate  cancer  tissues  (138, 
139).  Hypermethylation  of  the  GSTP1  promoter  is  a 
common  change  that  occurs  during  carcinogenesis 
a n d   i s   r e g a r d e d   t o   b e   a   m a i n   c h a r a c t e r i s t i c   o f   p r o s t a t e  
carcinogenesis (140). 
G S T P 1   h a s   b e e n   s h o w n   t o   b e   a c u t e l y  sensitive in 
detecting  the  presence  of  prostatic  intraepithelial 
neoplasia  and  prostrate  cancer,  thereby  distinguish-
ing  patients  with  these  diseases  from  patients  with 
BPH  (138,  141-145). Moreover, the increased hyper-
methylation of the GSTP1 gene in neoplastic  events 
can consistently distinguish between prostate cancer 
and BPH (146). With the help of PCR, the methylated 
G S T P 1   g e n e   h a s   a l s o   b e e n   d e t e c t e d   i n   t h e   u r i n e   o f   m e n  
w h o   h a v e   u n d e r g o n e   p r o s t a t e   b i o p s y .   T h i s   i m p l i e s   t h e  
possible  additional  use  of  this  biomarker  in 
risk-stratification of men undergoing prostate biopsy 
(147).  
GSTPI displays several good characteristics that 
make it a viable biomarker. For instance, it is highly 
prevalent in the disease condition, and clinicians are 
able to measure quantitatively the methylation status 
o f   t h e   g e n e   i n   b i o p s y / p r o s t a t e c t o m y   t i s s u e s   a n d   i n  
cells isolated from serum, urine, and seminal plasma 
( 1 4 8 ) .   I f   i t   i s   s u c c e s s f u l l y   v a l i d a t e d ,   G S T P 1   m e t h y l a-
tion testing of cells derived from samples of serum 
and urine may possess a significant clinical potential 
for early detection of prostate cancer and posttreat-
ment monitoring of the disease.  Journal of Cancer 2010, 1 
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Chromogranin A (CGA, GRN-A)  
C h r o m o g r a n i n   A   ( C G A   o r   G R N -A ) ,   p a r t   o f   t h e  
granin family of proteins, is an acidic protein that has 
been identified in all neuroendocrine cell types stu-
d i e d   a n d   i s   p r o d u c e d   i n   l a r g e r   a m o u n t s   t h a n   o t h e r  
s e c r e t e d   p r o t e i n s   b y   t h o s e   c e l l s .   A l s o   k n o w n   a s   s e-
c r e t o r y   p r o t e i n   I ,   i t   i s   e n c o d e d   b y   t h e   C H G A   g e n e   i n  
humans  (149-1 5 1 ) .   T h e   g r o w t h   o f   p r o s t a t e   c e l l s   h a s  
been found to be regulated by peptides derived from 
GRN-A (138). Because it is produced and secreted by 
prostate  cells,  GRN-A   h a s   b e e n   e x a m i n e d   f o r   i t s   d i-
agnostic  and  prognostic  values  as  a  biomarker  for 
prostate cancer (152). However, limited evidence to 
this point supports its usefulness beyond traditional 
methods  of  screening  (152,  153).  Based  on  past  stu-
dies,  GRN-A   c a n   b e   u s e d   t o   m o n i t o r   t h e   s u c c e s s   o f  
c a n c e r   t r e a t m e n t .   I t   c a n   a l s o   b e   u s e d   t o  predict  the 
o u t c o m e   o f   t h e   d i s e a s e   a n d   p r o g n o s e s   t h a t   a r e   a n-
drogen  independent.  These  predictions  would  be 
prior to any indication of PSA progression and would 
show increased levels of GRN-A correlated with un-
desirable results and diminished overall survival (151, 
154-157).  Therefore,  GRN-A   m a y   b e   v e r y   u s e f u l   a s   a  
prognostic factor in patients with advanced prostate 
cancer (153).  
Interestingly, some variations in measurements 
of  GRN-A  have  been  reported  between  two  assays 
commercially  available  for  discerning  BPH  from 
prostate cancer (158). Some discrepancies observed in 
the  measurements  result  from  the  fact  that  the  cha-
racterization  of  most  prostate  cancer  by  neuroendo-
crine cells is a temporary and reversible process; the 
neuroendocrine  markers  may  frequently  be  unde-
tectable,  and,  therefore,  a  subset  of  the  neuroendo-
crine cells may not possess any differentiation (159).  
Although an accurate distinction cannot be made 
between prostate cancer and BPH based on the levels 
o f   s e r u m   G R N -A,  these  levels  do  reflect  the  tumor 
stage and grade and may efficiently indicate a poor 
prognosis  following  endocrine  therapy  when  com-
bined with free or total PSA ratio (153, 155, 160-162). 
O n e   n o t e d   w e a k n e s s   o f   u s i n g   G R N -A   a s   a   b i o-
m a r k e r   i s   t h e   f a c t   t h a t   n e u r o e n d o c r i n e   c e l l s   d o  not 
reside in all prostate tumors. Another weakness is its 
inability to detect the disease at a very early stage, as 
r e p o r t e d   b y   o n e   g r o u p   ( 1 5 3 ) .   O n   t h e   o t h e r   h a n d ,   b a s e d  
o n   t h e   e x p r e s s i o n   o f   G R N -A in prostate cancer ana-
l y z e d   b y   s e r u m   i m m u n o a s s a y   a n d   t i s sue  immuno-
h i s t o l o g y   p r o c e d u r e s ,   i t   w a s   c o n c l u d e d   t h a t   G R N -A 
has clinical potential as a biomarker for early, pro-
gressive, and recurrent prostate cancer (163). There-
fore,  more  research  is  needed  to  clearly  define  the 
clinical value of GRN-A as a serum and tumor marker 
for prostate cancer.  
Prostate-specific Membrane Antigen (PSMA) 
PSMA is a cell surface membrane that was dis-
covered in 1987 and has been well characterized as a 
d i a g n o s t i c   a n d   p r o g n o s t i c   m a r k e r .   I t   i s   a   t y p e   I I  
integral  membrane  protein  that  exhibits  numerous 
enzymatic  activities  (40,  164).  Although  insufficient 
d a t a   e x i s t   r e g a r d i n g   i t s   b i o l o g i c a l   r o l e ,   P S M A   h a s   b e e n  
s e e n   t o   t r a n s l o c a t e   t o   t h e   p l a s m a   m e m b r a n e   i n   p r o s-
tate cancer cells, whereas it is located in the cytosol in 
normal prostate cells (165). PSMA has been detected 
in  prostate  tissues,  circulating  prostate  cancer  cells, 
a n d   s e r u m .   I t s   l e v e l s   m a y   c o r r e s p o n d   w i t h   p o o r   c l i n-
ical  outcome;  PSMA  levels  are  higher  in  primary 
p r o s t a t e   c a n c e r   a n d   m e t a s t a t i c   d i s e a s e ,   w i t h   m o r e  
t h a n   9 0 %   o f   t h e   p r o t ein prevalent in the disease (166). 
T h e   s e r u m   l e v e l s   o f   P S M A   i n c r e a s e   w i t h   a g e   a n d   a r e  
considerably higher in men above 50 years of age (79). 
However,  no  concrete  evidence  has  shown  a  rela-
tionship between high levels of serum PSMA and the 
aggressive disposi t i o n   o f   t h e   d i s e a s e ,   w h i l e   s o m e   h a v e  
observed a decrease in advanced cases of the disease 
(167).  In  an  attempt  to  better  measure  the  levels  of 
c i r c u l a t i n g   P S M A ,   a   s t u d y   r e v e a l e d   t h a t   s e r u m   l e v e l s  
o f   P S M A   i n   p r o s t a t e   c a n c e r   p a t i e n t s   v a r y   s i g n i f i c a n t l y  
when compared  to  those  of  healthy  men  and  those 
w i t h   B P H   ( 1 6 7 ) .   P S M A   a p p e a r s   t o   b e   u p r e g u l a t e d   i n  
patients with prostate cancer subsequent to hormone 
deprivation  therapy  (32),  which  further  reveals  that 
t h e   l e v e l s   o f   P S M A   i n   m e n   w i t h   p r o s t a t e   c a n c e r   i s  
considerably higher than in those with BPH or those 
free of disease. Several gene therapy strategies have 
a l s o   u s e d   t h e   P S M A   g e n e   p r o m o t e r   t o   t r a n s c r i p t i o n-
ally  regulate  the  cytotoxic  genes/agents  in  prostate 
c a n c e r   c e l l s   ( 1 6 7 ) .   H o w e v e r ,   t h e   p r o s t a t e   s p e c i f i c i t y   o f 
P S M A   a s   a   g e n e   t h e r a p y   t a r g e t   i s   l i m i t e d ,   b u t   i t   h a s  
lately been used as a target for immunotherapy (168). 
One  of  the  shortcomings  in  using  PSMA  as  a 
serum marker is that high levels have been noticed in 
patients with incident case of prostate cancer and in 
t h e   s e r u m   o f   b r e a s t   c a n c e r   p a t i e n t s .   T h i s   c o u l d   m a k e   i t  
difficult  in  some  cases  to  accurately  diagnose  men 
with prostate cancer (44, 169). Another shortcoming is 
t h a t   t h e   l e v e l s   o f   s e r u m   P S M A   i n c r e a s e   w i t h   a d v a n c-
i n g   a g e ,   w h i c h   c o u l d   r e s u l t   i n   s o m e   c o n f licting results 
if diagnosis is sought at that period in life (which is 
u s u a l l y   t h e   c a s e ) .   M o r e   s u f f i c i e n t   d a t a   i s   r e q u i r e d   t o  
determine  whether  this  biomarker  can  be  validated 
clinically for use in prostate cancer detection, moni-
t o r i n g   o f   t r e a t m e n t ,   o r   a s  a n   a c t u a l   m e a n s   o f   t r e a t m e n t  
(170). 
Prostate Stem Cell Antigen (PSCA) 
Prostate stem cell antigen is a membrane glyco-
protein predominantly expressed in the prostate. Al-Journal of Cancer 2010, 1 
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t h o u g h   t h e   e x p r e s s i o n   o f   P S C A   h a s   b e e n   r e v e a l e d   t o  
b e   u p r e g u l a t e d   i n   t h e   m a j o r i t y   o f   p r o state cancers, its 
biological role in prostate cancer is uncertain (159). 
Studies  have  implicated  PSCA  in  certain  stem  cell 
functions  like  androgen-independent  progression, 
metastasis, or signal transduction in many prostate 
cancer cells (169, 171-173).  PSCA expression is asso-
ciated with Gleason score, seminal vesicle invasion, 
and capsular invasion in prostate cancer; hence, it has 
potential  as  a  therapeutic  target.  A  correlation  was 
detected between the increase levels of PSCA expres-
sion  in  most  prostate  cancers  and  higher  Gleason 
g r a d e   a n d   m o r e   a d v a n c e d   t u m o r   s t a g e   ( 1 7 1 ) .   A   f u n c-
t i o n   f o r   P S C A   i n   p r o s t a t e   c a n c e r   p r o g r e s s i o n   i s   p r o-
p o s e d   f r o m   t h e   o b s e r v a t i o n   t h a t   i t   i s   j o i n t l y   a m p l i f i e d  
with  c-myc  (an  oncogene  and  factor  in  tumor  pro-
gression) in locally advanced  prostate  cancers  (159, 
160). When the mRNA of other circulating prostate 
m a r k e r s   l i k e   P S A   a n d   P S M A   w e r e   c o m p a r e d   w i t h  
that  of  PSCA,  researchers  observed  that,  although 
PSCA displayed inferior sensitivity and considerable 
inability to distinguish between   m a l i g n a n t   a n d   b e n i g n  
disease, its disease specificity and independent pre-
dictive value were the highest (174).  
Using  human  xenografts  grown  in  SCID  mice, 
researchers showed that anti-PSCA monoclonal anti-
b o d i e s   i n h i b i t e d   t u m o r   g r o w t h   a n d   m e t a s t a s i s   f o r m a-
tion  (175),  making  PSCA  potentially  available  for 
treating prostate cancer therapeutically using immu-
notherapeutic  procedures  (175-177).  Despite  the  re-
s e a r c h   r e v e l a t i o n s   a b o u t   P S C A   a n d   i t s   p o t e n t i a l ,   t h e r e  
are still no definitive conclusions regarding its being a 
serum marker. Factors that mitigate against PSCA as a 
candidate for further development include an inade-
q u a t e   n u m b e r   o f   p u b l i s h e d   s t u d i e s   s u p p o r t i n g   P S C A  
as a valuable clinical biomarker and the lack of better 
measuring  techniques  (97).  Therefore,  the  value  of 
P S C A   a s   a   t h e r a p e u t i c   t a r g e t   a n d   t h e   e x i s t i n g   r e l a t e d  
data must await more studies to further evaluate and 
determine its effectiveness as a clinical prostate cancer 
marker.  
Early Prostate Cancer Antigen (EPCA) 
Early prostate cancer antigen, originally discov-
e r e d   i n   1 9 9 1   i n   r a t   p r o s t a t e   t i s s u e   ( 1 7 8 ) ,   i s   a   n u c l e a r  
m a t r i x   p r o t e i n   l i n k e d   w i t h   t h e   n u c l e a r   t r a n s f o r m a-
tions that occur in early prostate cancer development 
( 1 7 9 ) .   T h e s e   p r o t e i n s   a r e   v i t a l   c o m p o n e n t s   o f   t h e  
nuclear matrix, a structure show n   t o   d i c t a t e   t h e   s h a p e  
and organization of the nucleus and reflect patterns of 
chromatin  transcription.  The  correlation  between 
variations  in  the  nuclear  matrix  and  the  nuclear 
pleiomorphism displayed in prostate cancer was first 
described by Getzenberg et al. (178). Following that, 
E P C A   w a s   f o u n d   i n   p r o s t a t e   c a n c e r   p r e c u r s o r   l e s i o n s ,  
specifically in prostatic intraepithelial neoplasia and 
proliferative inflammatory atrophy, as well as pros-
t a t e   c a n c e r   t i s s u e   ( 1 8 0 ) .   A l s o ,   t h e   p r o t e i n   h a s   b e e n  
identified in men with a preliminary negative biopsy 
but but who later developed the cancer (180, 181). The 
study of Uetsuki et al. provided further evidence that 
EPCA can be linked with early carcinogenesis as no 
r e l a t i o n s h i p   c o u l d   b e   f o u n d   b e t w e e n   E P C A   a n d   d i s-
ease stag e   o r   G l e a s o n   s c o r e   a f t e r   r a d i c a l   p r o s t a t e c t o-
my  (179).  Furthermore, recent  studies have  verified 
t h e   p o t e n t i a l   d i a g n o s t i c   v a l u e   o f   s e r u m   E P C A   b y  
demonstrating the ability of EPCA antibodies to rec-
ognize prostate cancer (182). Although EPCA appears 
not to be present in patients devoid of prostate cancer, 
i t   h a s   b e e n   d e t e c t e d   i n   s u r r o u n d i n g s   f r e e   o f ,   b u t   a d-
jacent to, the cancer (180). More studies are needed to 
f u r t h e r   c h a r a c t e r i z e   t h e   p r o t e i n   a s   a   s u i t a b l e   b i o-
marker to diagnose prostate cancer.  
Several studies have been conducted to evaluate 
a n d   p r o p o s e   o t h e r   t i s s u e   a n d   c i r c u l a t i n g   p r o s t a t e   t u-
m o r   m a r k e r s   s u c h   a s   r i s i n g   a n e u p l o i d y   a n d   p o l y p-
loidy  (associated  with  invasive  and  metastatic  tu-
m o r s )   a n d   b i o p s y   p l o i d y ,   w h i c h   m a y   a s s i s t   i n   p r e-
dicting a pathologic stage (183-188). Ki-67 expression, 
a s   a   m a r k e r   o f   p r o l i f e r a t i o n   i n d e x ,   h a s   b e e n   s h o w n   t o  
be  an  independent  predictor  of  recurrence  and  tu-
mor-specific  survival  (93,  189).  RT-PCR  has  shown 
some promise as a sensitive biomarker in identifying 
micrometastases in nonprostatic  sites,  such  as  PSA- 
and/or  PSMA-positive lymph  nodes, which are  not 
d e t e c t a b l e   b y   c o n v e n t i o n a l   p a t h o l o g y   ( 1 9 0 ) .   T h e   e x-
pressions of Bcl-2 and p53 have been extensively ex-
amined as prognostic markers in prostate tissue, and 
these markers may aid in predicting the response of 
localized prostate cancer to radiotherapy. However, 
their utility in predicting a pathologic stage has yet to 
be established (191, 192). Finally, serum immunoassay 
f o r   h K 2   b i o m a r k e r   ( a   P S A -related  protein,  Table  4) 
combined  wi t h   P S A   t e s t i n g   p r o v i d e s   i m p r o v e d   d i s-
crimination among men who had total PSA levels in 
t h e   4   t o   1 0   n g / m l   r a n g e   a n d   b e t w e e n   m e n   w i t h   b e n i g n  
prostate disease and those with prostate cancer (193, 
1 9 4 ) .   S o m e   s t u d i e s   h a v e   i n d i c a t e d   t h a t   s e r u m   h K 2  
levels aid in predicting  prostate-confined  disease  in 
the staging preceding a surgical operation (194, 195).  
B7-H3 
B7-H3 is the first immune molecule that possibly 
p a r t i c i p a t e s   i n   t h e   d e v e l o p m e n t   o f   p r o s t a t e   c a n c e r   a n d  
i n   p r e d i c t i n g   t h e   r e c u r r e n c e   a n d   p r o g r e s s i o n   o f   c a n-
cer. B7-H3, first identified in 2001, is a member of the 
B 7   f a m i l y ,   a   g r o u p   o f   p r o t e i n s   t h a t   a r e   i m p o r t a n t   l i-
gands  interacting  with  known  and  unknown  recep-Journal of Cancer 2010, 1 
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tors to regulate the activation and function of T lym-
phocytes. B7 (or B7-H3) protein is believed to function 
as an accessory co-r e g u l a t o r   o f   T   c e l l   r e s p o n s e s   s u b-
sequent  to  initial  antigen  priming  (196,  197).  B7 
co-regulatory ligands can be abnormally expressed in 
human disease and may act as antigen-specific inhi-
bitors  of  T-cell–mediated  antitumoral  immunity  in 
cancer conditions (198). The B7-H family protein, in-
cluding  B7-H3  and  B7-H1,  can  both  arrest  cancer 
g r o w t h   a n d   s h i e l d   c a n c e r s   f r o m   t h e   i m m u n e   s y s t e m  
b y   p a r a l y z i n g   i m m u n e   c e l l s   ( 1 9 9 ) .   T h e r e b y   t h i s   l i g a n d  
exhibits both an immune stimulatory and inhibitory 
role in cancer growth. 
Numerous  normal  tissues,  except  for  dormant 
peripheral  blood  monocytes,  express  B7-H3  mRNA 
(196, 200). B7-H3 protein expression has been detected 
in placenta (201), and its expression can be stimulated 
in  activated  dendritic  c e l l s ,   m o n o c y t e s ,   a n d   T   c e l l s  
(202). B7-H 3   i s   a l s o   e x p r e s s e d   i n   n u m e r o u s   t u m o r   c e l l  
lines, and the expression of B7-H3 in carcinomas of 
the  kidney  and  bladder  correlates  with  aggressive 
disease and significantly shortened survival time in 
patients. The expr e s s i o n   o f   t h e s e   p r o t e i n s   i n   p r o s t a t e  
cancer has been linked to the spread of the disease 
a n d   n e g a t i v e   o u t c o m e   ( 2 0 3 -2 0 5 ) .   I n   c o n t r a s t   t o   P S A ,  
B7-H 3   r e m a i n s   b o u n d   t o   t h e   s u r f a c e   o f   n o r m a l   p r o s-
tate cells, as well as of premalignant and cancerous 
prostate  cells  that  show  no  apparent  indication  of 
migration  (metastatic  ability),  thus  making  it  an  at-
tractive therapeutic target and marker. This would be 
an especially promising target for antihormone ther-
a p y ,   w h i c h   i s   t h e   m o s t   f r e q u e n t   m e a n s   o f   t h e r a p e u t i c  
treatment for advanced prostate cancer (203). Because 
B7-H 3   i s   p r e s e n t   i n   a l l   p r o s t a t e   c a n c e r   t u m o r s   a n d  
marked  levels  predict  recurrence,  researchers  ex-
a m i n e d   d i s e a s e d   t i s s u e   f r o m   3 3 8   p a t i e n t s   w h o   h a d  
clinically localized prostate cancer and were treated 
exclusively with radical prostatectomy between 1995 
a n d   1 9 9 8 .   T h e y   w e r e   a b l e   t o   p r e d i c t   w i t h   b e t t e r   a c c u-
r a c y   t h e   l i k e l i h o o d   o f   c a n c e r   p r o g r e s s i o n   i n   s p i t e   o f  
therapeutic intervention (203). This study revealed a 
link between a rising level of B7-H3 in prostate cancer 
and adverse clinicopathologic features of the disease. 
Therefore, B7-H 3   m a y   h a v e   t h e   p o t e n t i a l   t o   i n d e p e n-
dently predict prostate cancer progression and may 
b e   u s e d   a s   a   d i a g n o s t i c   a n d   p r o g n o s t i c   m a r k e r   t o  
evaluate patients’ disease status and their immuno-
therapeutic responses (203,205). 
More research is necessary, however, to under-
s t a n d   h o w   t h e   i m m u n e   s y s t e m   i s   a f f e c t e d   b y   B 7 -H3. 
F o r   e x a m p l e ,   i t   w o u l d   b e   u s e f u l   t o   k n o w   w h e t h e r   a n-
ti-i m m u n e   a c t i v i t y   r e s u l t s   f r o m   a   m u t a t i o n   o f   B 7 -H3, 
w h i c h   m a y   b e   t h e   m e c h a n i s m   b y   w h i c h   B 7 -H3  pro-
motes cancer growth. This information is critical and 
w i l l   h e l p   t o   e s t a b l i s h   t h e   e f f e c t i v e n e s s   o f   B 7 -H3 as a 
clinical marker of disease and target for therapy. 
Sarcosine 
Sarcosine, an N-methyl derivative of glycine, is a 
natural amin o   a c i d   f o u n d   i n   m u s c l e s   a n d   o t h e r   b o d y  
tissues.  It is classified  under  the  group  collectively 
k n o w n   a s   m e t a b o l i t e s   ( a   g r o u p   o f   c h e m i c a l   p r o d u c t s  
present throughout the body) (206). In 2009, Sreeku-
m a r   e t   a l .   r e p o r t e d   t h a t   s a r c o s i n e   s t i m u l a t e s   m a l i g-
nant grow t h   o f   b e n i g n   p r o s t a t e   c a n c e r   c e l l s   a n d   c a n   b e  
used as an indicator of the malignancy of prostate 
cancer cells when detected in urine (207). Following 
t h e   s c r e e n i n g   o f   u r i n e ,   b l o o d ,   a n d   t i s s u e s ,   a n d   p r o f i l-
ing  more  than  1,126  metabolites  related  to  prostate 
cancer, the researchers were able to differentiate be-
tween  benign  prostate,  clinically  localized  prostate 
cancer, and metastatic disease based on the levels of 
sarcosine. The levels of sarcosine were high in inva-
sive  prostate  cancer  cell  lines  compared  to  benign 
prostate epithelial cells (207). Furthermore, it was ob-
served that prostate cancer invasion was weakened 
when  glycine-N-methyltransferase,  the  enzyme  that 
catalyzes  the  production  of  sarcosine  from  glycine, 
was  knocked  down,  whereas  either  knocking down 
the enzyme responsible for sarcosine degradation or 
adding  exogenous  sarcosine  stimulated  an  invasive 
phenotype in BPH cells. These results together sug-
g e s t   t h a t   s a r c o s i n e   m a y   b e   a   v i t a l   m e t a b o l i c   i n t e r m e-
diary that promotes prostate cancer cells toward in-
vasion and aggressiveness (208).  
T h e   u l t i m a t e   g o a l   o f   d i a g n o s i s   i s   t o   d e t e c t   a g-
gressive-type  prostate  cancers  at  their  premature 
stage.  This,  nevertheless,  may  not  be  possible  very 
soon. Among the conflicting scientific points of view 
on whether sarcosine is a better diagnostic biomarker 
than PSA for detecting aggressive prostate cancer is 
that several researchers have been criticized for their 
possible investment interests in promoting sarcosine 
toward  commercialization.  Moreover,  further  inves-
tigatio n s   a r e   s t i l l   n e e d e d   o n   t h e   m e t a b o l i t e s   i n   m a n y  
patients who are followed long-term (to see how they 
correlated with those who developed different forms 
of prostate cancer).  
Caveolin-1 
Caveolin-1 (Cav-1), an integral membrane pro-
tein  expressed  in  two  isoforms  (caveolin-1α  and 
caveolin-1β),  i s   a   m a i n   c o m p o n e n t   o f   c a v e o l a e   m e m-
branes in vivo ( 2 0 9 ) .   I t   h a s   b e e n   i m p l i c a t e d   i n   r e g u l a t-
ing several signaling pathways and mediating intra-
cellular processes, specifically as a negative regulator 
in several mitogenic pathways (210) and in oncoge-
n e s i s   ( 2 1 1 ) .   I t   h a s   b e e n   p r o p o s e d   t h a t   C a v -1   m a y   p a r-Journal of Cancer 2010, 1 
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ticipate in certain steps of carcinogenesis in various 
t y p e s   o f   c a n c e r   a n d   i s   e x p r e s s e d   i n   o n e -third of inva-
sive breast cancers (212). Cav-1   s e e m s   t o   f u n c t i o n   a s   a  
tumor  suppres s o r   p r o t e i n   a t   e a r l y   s t a g e s   o f   c a n c e r  
progression.  However,  Cav-1   i s   a l s o   f o u n d   t o   b e  
u p r e g u l a t e d   i n   s e v e r a l   m e t a s t a t i c   a n d   m u l t i-
drug-resistant  cancer  cell  lines,  as  well  as  in  some 
human tumor specimens (213). 
Cav-1 is secreted by prostate cancer cells. Early 
a n d   r e c e n t   s t u d i e s   h a v e   s h o w n   t h a t   t h i s   s e c r e t e d   p r o-
tein can promote cell survival and angiogenic activi-
ties (214-216). Cav-1 has been reported to be overex-
pressed in prostate cancer cells and is associated with 
the progression of the disease (217-218).  
S t u d i e s   o f   p r o s t a t e   t i s s u e   f r o m   m e n   w i t h   o n l y  
localized  prostate  cancer  indicate  a  significant  de-
crease in levels of Cav-1 .   I t   w a s   a l s o   d i s c o v e r e d   t h a t  
t h e   p r o t e i n   w a s   a b s e n t   i n   t u m o r   t i s s u e   f r o m   m e n   w i t h  
metastatic prostate cancer, and the reduced levels  of 
Cav-1  were  associated  with  a  high  Gleason  score 
(220). 
Research conducted on stromal Cav-1 expression 
i n   p a t i e n t s   w i t h   B P H ,   p r i m a r y   p r o s t a t e   c a n c e r s ,   a n d  
prostate  cancer  metastases  revealed  that  almost  all 
BPH  samples  showed  an  abundant  stromal  Cav-1 
immunostaining, while a subset of samples with pri-
mary prostate cancer had significantly decreased le-
v e l s   o f   s t r o m a l   C a v -1.  All  metastatic  tumors  (either 
from  lymph  node  or  bone)  lacked  stromal  Cav-1 
s t a i n i n g   ( 2 2 1 ) .   T h e   c o n c e n t r a t i o n   o f   p r e o p e r a t i v e   s e-
rum  Cav-1  showed  prognostic  potential  in  patients 
undergoing  radical  prostatectomy  (220).  Therefore, 
Cav-1   e x p r e s s i o n   m a y   b e   a   u s e f u l   p r o g n o s t i c   m a r k e r  
for prostate cancer (220, 222). 
Serum calcium  
Prostate  cancer  cells  express  calcium-sensing, 
G-protein-coupled  receptor,  which  can  be  activated 
by extracellular calcium (223). These cells also express 
calcium-dependent potassium channels that regulate 
their proliferation by controlling the entry of calcium 
i n t o   t h e   c e l l s   ( 2 2 4 ) .   A n   a s s o c i a t i o n   h a s   b e e n   n o t e d  
between high levels of total calcium in serum and the 
r i s k   o f   f a t a l   p r o s t a t e   c a n c e r ,   w h i c h   i s   t o   t h e   r e s u l t   o f   a  
decrease in apoptosis and an increase in proliferation, 
w h i c h   p r o m o t e   t h e   g r o w t h   a n d   m e t a s t a s i s   o f   p r o s t a t e  
cancer  cells  (225).  Researchers  postulated that an in-
c r e a s e   i n   s e r u m   c a l c i u m   o r   a n y   f a c t o r   t h a t   l e a d s   t o   i t  
( s u c h   a s   h i g h   s e r u m   p a r a t h y r o i d   h o r m o n e )   w o u l d  
increase the possibility for terminal prostate cancer. 
An investigation by an independent group confirmed 
this association and suggested that serum calcium is a 
promising  prospective  biomarker  for  screening  for 
fatal prostate cancer (225-227). 
Hypermethylation of PDLIM4 gene 
Hypermethylation of the PDLIM4 gene has been 
shown to be a sensitive molecular tool in detecting 
prostate  tumorigenesis  (228).  PDLIM4  mRNA  and 
protein  expression  levels  were  also  reduced  in 
LNCaP,  LAPC4,  DU145,  CWR22,  and  PC3  prostate 
cancer cells and may function as a tumor suppressor 
b y   a s s o c i a t i n g   w i t h   a c t i n   i n   p r o s t a t e   c a n c e r   c e l l s ,   t h e-
reby  controlling  cell  proliferation  (229).  These  find-
ings  support  the  potential  use  of  hypermethylated 
PDLIM4 as a biomarker to predict the biochemical, 
local, and systemic recurrence of prostate cancer. 
PCA3/DD3 
The prostate cancer antigen 3 (PCA3 or DD3) 
gene encodes a prostate-specific mRNA that is over-
expressed  in  cancer  prostate  tissue  (230,  231).  A 
m e a s u r e   o f   t h e   q u a n t i t y   o f   P C A 3   R N A   c o p i e s   i n   u r i n e  
s a m p l e s   t h a t   a r e   e n r i c h e d   w i t h   p r o s t a t e   c e l l s   c a n   p r o-
vide an insight into the aggressiveness of the prostate 
cancer (232) and  predict the outcome of prostate bi-
opsies while avoiding the need for repeated testing 
(233-2 3 5 ) .   F u r t h e r m o r e ,   t h e   p r e d i c t i v e   v a l u e   o f   P C A 3  
has been addressed in some clinical studies, either by 
u r i n e   t e s t   t h a t   i s   p e r f o r m e d   p r i o r   t o   r a d i c a l   p r o s t a-
t e c t o m y   o r   b y   e x t racapsular extension prior to a DRE 
exam  (236,  237).  Consequently,  several  published 
studies have supported the usefulness of PCA3 as a 
b i o m a r k e r   i n   t h e   d i a g n o s i s   o f   p r o s t a t e   c a n c e r   s t a g e  
and grading (231-235, 239-244). Although PCA3 has a 
lower sensitivity   t h a n   d o e s   P S A ,   i t   h a s   a   h i g h e r   s p e c i-
ficity (233-235), especially in certain cases where PSA 
tests  fail  to  accurately  predict  disease  (245,  246). 
A d d i n g   P C A 3   t o   s e r u m   P S A   d e t e c t i o n   c o n t r i b u t e s   t o  
t h e   p r e c i s e   p r e d i c t i o n   o f   p r o s t a t e   c a n c e r ;   i n   a   c l i n i c a l  
set t i n g ,   P C A 3   m a y   b e   u s e d   t o   c l a s s i f y   p a t i e n t s   a c-
c o r d i n g   t o   t h e i r   r i s k s   f o r   b i o p s y   a n d   c a n c e r   d e t e c t i o n  
(238,  245-246).  Similarly,  combining  urinary  al-
pha-methylacyl-CoA  racemase  (AMACR)  and  PCA3 
a s   a   d u a l   m a r k e r   t e s t   i m p r o v e d   s e n s i t i v i t y   a n d   a c c u-
racy (247). A recent study reported an upregulation of 
two  new  PCA3 isoforms in  prostate  cancer  tissues; 
this will enhance the diagnostic ability to distinguish 
between prostate cancer and BPH (248). 
TMPRSS2-ERG Gene Fusion Rearrangement 
Transmembrane protease serine 2 ,   a l s o   k n o w n   a s  
TMPRSS2,  is  an  androgen-regulated,  type  II  trans-
membrane-bound serine protease that is locally ex-
pressed in the prostate and overexpressed in neoplas-
tic prostate epithelium. TMPRSS2 was thought to play 
a   p o s s i b l e   r o l e   i n   p r o s t a t e   t u m o r   m e tastasis through 
the  activation  of  protease-activated  receptor-2 
(PAR-2)  (249). An extensive study focusing on gene Journal of Cancer 2010, 1 
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fusion  transcripts  in  prostate  cancer  identified  the 
fusion between TMPRSS2 (located at 21q22.3) with the 
transcription  factor  genes  ERG  (21q22.2)  and  ETV1 
(7p21.1)  (250,  251).  One  TMPRSS2  allele  loses  its 
p r o m o t e r ,   a n d   o n e   o f   t h e   E R G   a l l e l e s   g a i n s   i t ,   r e s u l t-
ing in an overexpression of ETS family members) in 
the  cancer  cells  (252)  and  consequently  tumor  pro-
gression  (253).  T h e   g e n e   f u s i o n   r e a r r angements  be-
tween  TMPRSS2  and  ERG  or  ETV1  have  been  re-
ported in several cancers, particularly in hematologi-
cal  malignancies  (254).  TMPRSS2-E R G   i s   t h e   m o s t  
frequent  oncogenic  gene  fusion  rearrangement  in 
p r o s t a t e   c a n c e r   ( 2 5 1 ) :   I t   h a s   b e e n   o b s e r v e d   i n   a l m o s t  
h a l f   o f   p r o s t a t e   c a n c e r   p a t i e n t s   a n d   d e t e c t e d   i n   a b o u t  
one-quarter  of  patients  with  prostatic  intraepithelial 
neoplasia (PIN) (255).  
This  TMPRSS2-ERG fusion is usually found in 
p r o s t a t e   c a n c e r   t i s s u e   f r o m   m e n   u n d e r g o i n g   p r o s t a-
tectomy, and especially among men in North America 
with  prostate  cancer  on  biopsy;  however,  it  is  not 
present in benign prostate biopsy. The TMPRSS2-ERG 
f u s i o n   c a n   b e   d e t e c t e d   i n   t h e   u r i n e   a f t e r   D R E   w i t h   a  
37% sensitivity and a 93% specificity (256). The addi-
tion  of  TMPRSS2–ERG  detection also increased the 
s e n s i t i v i t y   o f   t h e   u r i n e   P C A 3   t e s t   f r o m   6 2 %   t o   7 3 %  
( 2 5 6 )   a n d   a   g r e a t e r   p r e d i c t i o n   o f   p o s i t i v e   t u m o r s   w i t h  
a   h i g h e r   G l e a s o n   s c o r e   ( 2 5 7 ) .   T h e   r e s u l t s   s u g g e s t   t h a t  
surveillance of these fusion gene transcripts improves 
the sensitivity of the PCA3 detection in urine samples: 
The  combination  of  TMPRSS2-ERG  detection  with 
PCA3  can  be  very  useful  in  accurately  predicting 
prostate cancer development during screening (252, 
258). 
Exosomes  
Exosomes are nanometer-sized vesicles secreted 
by a bro a d   r a n g e   o f   n o r m a l   a n d   n e o p l a s t i c   c e l l   t y p e s  
( 2 5 9 ) .   T h e y   c o n t a i n   b o t h   f u n c t i o n a l   m R N A   a n d   m i-
croRNA, called exosomal shuttle RNA (esRNA) that 
a r e   o f t e n   t r a n s p o r t e d   f r o m   c e l l   t o   c e l l   w h e r e   t h e y   c a n  
continue to be functional (260). Exosmes are consti-
tuents of urine, with a degree of variability in urine 
specimens. Because they often carry genetic compo-
n e n t s   t h a t   c o m e   d i r e c t l y   f r o m   t u m o r s ,   s u c h   v e s i c l e s  
m a y   b e   a   u s e f u l   n o n i n v a s i v e   s o u r c e   o f   m a r k e r s   i n  
renal diseases (251), including cancer of the prostate. 
 A recent study reported the presence of PCA3 
and TMPRSS2-ERG fusion, two known prostate can-
cer biomarkers, in exosomes from urine samples of 
prostate cancer patients (261, 262). A second study 
reported  the  presence  of  the  gene  fusion 
TMPRSS2-E R G   p r o d u c t   i n   i solated  exosomes  in  the 
serum from mice grafted with human PCA xenografts 
( 2 6 3 ) ,   w h i c h   c o u l d   s h e d   m o r e   l i g h t   o n   t h e   g e n e t i c s   o f  
the  particular  tumor  and  provide  clinically  valuable 
data.  Although  the  presence  of  exosomes  in  urine 
samples varies in concentration, making it difficult to 
assess, its presence and quantification may be a po-
tential  noninvasive  source  of  tumor  markers  that 
c o u l d   b e   u s e d   t o   d i a g n o s e   a n d   m o n i t o r   t h e   s t a t u s   o f  
prostate cancer. 
Ki-67 
 Ki-67, a cell-proliferation associated marker and 
probably the only protein with an expression pattern 
u n d e r   a   l e v e l   o f   c e l l   c y c l e   r e g u l a t i o n   ( 2 5 5 ,   2 6 4 ) ,   h a s  
b e e n   d e s c r i b e d   a s   o n e   o f   t h e   m o s t   p r o m i s i n g   b i o-
markers of prostate cancer. Ki-67 has been suggested 
as a prolific predictive biomarker for men who have 
low-grade,  low-stage  prostate  cancer  for  their  PSA 
relapse after radical prostatectomy (265). In a 6-year 
study involving 808 patients diagnosed with prostate 
cancer, an immunohistochemical assessment of Ki-67 
e x p r e s s i o n   w a s   e v a l u a t e d   f o r   i t s   r e l a t i o n s hip  to  the 
s p e c i f i c i t y   o f   t h e   c a n c e r   a n d   o v e r a l l   s u r v i v a l .   C o m-
pared to information from the Gleason score and PSA, 
Ki-67  provided  additional  prognostic  information 
(266, 267). In another study of a   g r o u p   o f   m e n   t r e a t e d  
with  radiotherapy  and  androgen  deprivation  for 
prostate cancer, Ki-67 expression levels in conjunction 
w i t h   M D M 2   w e r e   f o u n d   t o   b e   c o r r e l a t e d   t o   d i s t a n t  
metastasis and survivability (268). Nevertheless, fur-
ther studies will be needed to validate these results 
and explore the possibility of combining  Ki-67  with 
existing prognostic tools as a powerful biomarker for 
localized prostate cancer (269). 
GOLPH2 
Golgi phosphoprotein 2, or GOLPH2, is a gene 
t h a t   c o d e s   f o r   t y p e   I I   G o l g i   m e m b r a n e   a n t i g e n  
G O L P H 2 / G P 7 3 .   I t   i s   u s u a l l y   e x p r e s s e d   i n   v a r i o u s  
epithelial cells and reported to be frequently overex-
pressed in cancer of the prostate, although its function 
is currently unknown (270). A   s t u d y   h a s   o b s e r v e d   a  
h i g h e r   l e v e l   o f   G O L P H 2   a n d   M Y O 6   ( m y o s i n   V I )   i n   t h e  
Golgi apparatus in prostate cancer cells compared to 
normal Golgi, thereby indicating that GOLPH2 can be 
u s e d   a s   a   b i o m a r k e r   i n   d i s t i n g u i s h i n g   b e t w e e n   n o r-
mal cells and cancer cells (271). 
 A recent study, which explored the expression 
o f   s o m e   p o t e n t i a l   p r o s t a t e   c a n c e r   b i o m a r k e r s ,   r e-
vealed that an increase in the levels of GOLPH2 (as 
w i t h   s o m e   o f   t h e   o t h e r   b i o m a r k e r s   a s s a y e d ) ,   w a s   n o t  
o n l y   a   c r i t i c a l   i n d i c a t o r s   o f   p r o s t a t e   c a n c e r   b u t   p e r-
formed better than PSA or PCA3 alone in revealing it 
(272). 
A   c o m p a r a t i v e   s t u d y   o f   G O L P H 2   p r o t e i n ,   t h e  
basal cell marker  p63,  and  AMACR  in  benign  and Journal of Cancer 2010, 1 
 
http://www.jcancer.org 
169 
malignant  prostate  lesions  revealed  that  GOLPH2 
expression was considerably higher in prostate cancer 
t i s s u e s   c o m p a r e d   w i t h   n o r m a l   t i s s u e s ,   a n d   i n   a b o u t  
9 0 %   o f   t h e   c a s e s   s t u d i e d ,   G O L P H 2   p r o t e i n   w a s  
upregulated. Furthermor e ,   t h i s   u p r e g u l a t i o n   w a s   n o-
t i c e d   i n   a b o u t   8 5 %   o f   p r o s t a t e   c a n c e r   c a s e s   t h a t   w e r e  
negative for AMACR (273).  
DAB2IP 
DAB2  interacting  protein  (DAB2IP)  is  a  Ras 
GTPase-activating  protein  that  functions  as  a  tumor 
suppressor. The  human DAB2IP  gene  is  located  on 
chromosome 9q33.1-q33.3 (274) and is frequently ob-
s e r v e d   t o   b e   d o w n r e g u l a t e d   i n   p r o s t a t e   c a n c e r   c e l l  
l i n e s   ( 2 7 5 ,   2 7 6 ) .   S t u d i e s   h a v e   s h o w n   t h a t   l o s s   o f   e x-
pression o f   D A B 2 I P   m a y   b e   a   r e s u l t   o f   a l t e r e d   e p i g e-
netic regulations, for example DNA methylation and 
histone modification (277). The abnormal methylation 
i n   t h e   p r o m o t e r   r e g i o n   o f   t h e   D A B 2 I P   g e n e   h a s   b e e n  
r e p o r t e d   t o   b e   r e s p o n s i b l e   f o r   t r a n s c r i p t i o n a l   s i l e n c i n g  
and  consequently  performs a significant function in 
t h e   p r o g r e s s i o n   o f   p r o s t a t e   c a n c e r   ( 2 7 8 ) .  Duggan et al. 
i n   t h e i r   2 0 0 7   s t u d y   r e p o r t e d   a   l i n k   b e t w e e n   a   g e n e t i c  
variation in DAB2IP and the risk of aggressive pros-
tate cancer (279). This research indicates that DAB2IP 
protein, after further studies, can potentially be used 
as a very effective novel biomarker for prostate cancer 
diagnosis.  
7. FUTURE CHALLENGES AND 
PERSPECTIVES 
The  increasing  importance  of  biomarkers  in 
s c r e e n i n g   f o r   p r o s t a t e   c a n c e r   t o   r e d u c e   i n v a s i v e   f o l-
low-up procedures is reflected proportionally in the 
rapidly increasing number of research publications in 
this field. The application of biomarkers to prostate 
cancer is at the forefront of the research field because 
of the distinctive relationship between the genomic 
changes in the cancer cells and the disease progress. 
The  technolog y   u s e d   i n   t h e   e f f o r t   t o   d i s c o v e r  
ideal biomarkers has advanced significantly, making 
i t   e a s i e r   t o   s t u d y   m a n y   p o t e n t i a l   b i o m a r k e r s   i n   a   s i n-
gle  trial.  While  several  biomarkers  have  displayed 
some  potential  in  early-p h a s e   s t u d i e s ,   n o n e   s o   f a r  
appears likely t o   p o s s e s s   t h e   a p p r o p r i a t e   l e v e l   o f   s e n-
sitivity  and  specificity  in  terms  of  determining  the 
choice and course of therapeutic treatment for  pros-
tate cancer (98).  This  may explain why only a small 
number of biomarkers are routinely validated for use 
in drug development or qualified for clinical applica-
tions, despite the apparent progress in this research 
field. Despite some  advancement, several limitations 
still exist with the current technology that hinders the 
d i s c o v e r y   a n d   d e v e l o p m e n t   o f   n e w   b i o m a r k e r s   f o r  all 
forms  of  cancer  including  prostate  cancer.  Some  of 
these  impediments  may  be  overcome  through  the 
development  of  new  technologies  and  improved 
strategies. For example, one strategy proposed would 
pair the diagnostic test with the therapeutic agent (6). 
Another  strategy  calls  for  more  attention  on  studies 
that  can  generate  quantified  biomarkers  related  to 
cell-s i g n a l i n g   p a t h w a y s ,   a s   t h e s e   b i o m a r k e r s   c a n   b e  
a p p l i e d   a c r o s s   a   w i d e   r a n g e   o f   t u m o r   t y p e s   a n d   d i s-
eases, as well as in different tests and drugs (10, 12). 
 B e c a u s e   o f   t h e   f a c t   t h a t   t h e   e n t i r e   p r o c e s s   f r o m  
identifying to validating a reliable biomarker is ex-
pensive and long, concerns have been raised over the 
profit-making incentives to develop novel biomark-
ers. An expensive search in the long run would result 
i n   a   h i g h   c o s t   f o r   a n y   r e l i a b l e   t e s t   d e v e l o p e d   i n   t h e  
future, adding even more cost to the already high cost 
o f   d r u g   d e v e l o p m e n t   ( 1 2 ) .   C o n s e q u e n t l y ,   p h a r m a-
ceutical companies may gradually become reluctant 
to  invest  in  diagnostic  development  in  the  earlier 
p h a s e s   o f   t e s t i n g   b e c a u s e   o f   t h e   u n c e r t a i n t y   o f   v a l i d a-
tion and approval by the FDA, without which there 
will be no financial return on all of their investment.  
A critical point that has been reiterated is the fact 
t h a t   a n   i d e a l   b i o m a r k e r   h a s   t o   show a high level of 
specificity  and  sensitivity  to  prevent  false-positive 
screening tests, which will create anxiety in patients 
a n d   l e a d   t o   m o r e   e x p e n s i v e   a n d   i n v a s i v e   t e s t i n g .   T h u s  
far,  studies,  although  inconclusive,  have  found  that 
the likelihood of identifying  a  biomarker  with  such 
sensitivity and specificity may be slim, at least for the 
immediate  future.  Therefore,  combining  markers  is 
thought to be the next best thing to improve the ac-
curacy  of  diagnosing,  treating,  and  surveillance  of 
recurrence of   p r o s t a t e   c a n c e r   ( 1 5 2 ) .   S o m e   h a v e   s u g-
gested  using  multiple  biomarkers  with  different 
qualities: for instance, combining a “biomarker with 
high sensitivity and low specificity (to detect poten-
tially deadly cancers but would result in many false 
positives) w i t h   a   s e c o n d   b i o m a r k e r   h a v i n g   l e s s   s e n s i-
tivity but higher specificity” (84). 
In summary, substantial discovery still awaits to 
be made in this field, and methodologies for the clin-
ical evaluation of existing and novel biomarkers have 
yet to be explored. Wh i l e   m u c h   c o u l d   b e   g a i n e d   f r o m  
t h e   d i s c o v e r y   o f   m o r e   n o v e l   b i o m a r k e r s   f o r   e a r l y   d e-
tection of prostate cancer, prediction of the malignant 
potential of the disease, and guidance of individua-
l i z e d   t h e r a p y   f o r   p a t i e n t s ,   t h e   n e a r   f u t u r e   o f   p r o s t a t e  
cancer progn o s i s   m a y   e v e n t u a l l y   c o m e   t o   c o u n t   o n   a  
few  “elite  club”  biomarkers,  which  hopefully  will 
accurately predict the incidence, stage, and progres-
s i o n   o f   t h e   d i s e a s e ,   a s   w e l l   a s   r e l i a b l y   e v a l u a t e   d r u g  
development.  While  extensive  clinical  validation  of Journal of Cancer 2010, 1 
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these novel  biomarkers  remains  as  one  of  the  most 
significant and daunting challenges, overcoming this 
impediment will by no means eliminate all the prob-
lems hampering the identification and development 
o f   b i o m a r k e r s   f o r   t h i s   d i s e a s e .   H o w e v e r ,   i n   t h e  
process of se a r c h i n g   f o r   n o v e l   b i o m a r k e r s ,   w e   m a y  
discover  valuable  insights  into  the  mechanisms  of 
p r o s t a t e   c a n c e r   t h a t   c o u l d   p o s s i b l y   l e a d   t o   a   c u r e   i n  
the long run. 
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